---
document_datetime: 2023-09-21 18:21:01
document_pages: 53
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/zinforo-h-c-2252-ii-0022-epar-assessment-report-variation_en.pdf
document_name: zinforo-h-c-2252-ii-0022-epar-assessment-report-variation_en.pdf
version: success
processing_time: 98.6349779
conversion_datetime: 2025-12-28 17:48:58.662859
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 April 2016 EMA/CHMP/325573/2016 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Zinforo

International non-proprietary name: ceftaroline fosamil

Procedure No. EMEA/H/C/002252/II/0022

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 5                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................5                                                 |
| 2. Scientific discussion................................................................................                   | 7                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................7 |
| 2.2. Non-clinical aspects..............................................................................................8   |                                                                                                           |
| 2.2.1. Introduction......................................................................................................8 |                                                                                                           |
| 2.2.2. Pharmacology...................................................................................................8    |                                                                                                           |
| 2.2.3. Pharmacokinetics                                                                                                    | ..............................................................................................8           |
| 2.2.4. Toxicology........................................................................................................9 |                                                                                                           |
| 2.2.5. Ecotoxicity/environmental risk assessment.........................................................                  | 12                                                                                                        |
| 2.2.6. Discussion on non-clinical aspects .....................................................................            | 12                                                                                                        |
| 2.2.7. Conclusion on the non-clinical aspects ...............................................................              | 14                                                                                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 16     |
| 2.3.1. Introduction....................................................................................................    | 16                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 16           |
| 2.3.3. Discussion on clinical pharmacokinetics..............................................................               | 32                                                                                                        |
| 2.3.4. Conclusions on clinical pharmacology.................................................................               | 33                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 34     |
| 2.4.1. Main studies                                                                                                        | ................................................................................................... 34    |
| 2.4.2. Discussion on clinical efficacy............................................................................         | 44                                                                                                        |
| 2.4.3. Conclusions on the clinical efficacy                                                                                | .................................................................... 44                                   |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 44   |
| 2.5.1. Discussion on clinical safety..............................................................................         | 51                                                                                                        |
| 2.5.2. Conclusions on clinical safety ............................................................................         | 51                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 51  |
| 2.6. Risk management plan .......................................................................................          | 51                                                                                                        |
| 2.7. Update of the Product information........................................................................             | 51                                                                                                        |
| 2.7.1. User consultation ............................................................................................      | 51                                                                                                        |
| 3. Benefit-Risk Balance.............................................................................                       | 52                                                                                                        |
| 4. Recommendations.................................................................................                        | 52                                                                                                        |
| 5. EPAR changes .......................................................................................                    | 53                                                                                                        |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| % f T>MIC   | Percent time of free-drug concentration above the minimum inhibitory concentration (MIC) over the dose interval   |
|-------------|-------------------------------------------------------------------------------------------------------------------|
| AUC         | Area under the plasma concentration versus time curve                                                             |
| AUC24SS     | Area under the plasma concentration versus time curve over 24 hours at steady-state                               |
| AUC(0-t)    | Area under the plasma concentration-time curve from zero to time of last quantifiable concentration               |
| AUC(0-τ)    | Area under the plasma concentration versus time curve from time 0 to the end of the dosing interval, τ            |
| AUC0-∞      | Area under the plasma concentration versus time curve from time 0 to infinity                                     |
| BSA         | Body surface area                                                                                                 |
| CAP         | Community-acquired pneumonia                                                                                      |
| CDS         | Core data sheet                                                                                                   |
| CE          | Clinically evaluable                                                                                              |
| CLD         | Haemodialysis clearance                                                                                           |
| Cmax        | Maximum plasma drug concentration                                                                                 |
| CmaxSS      | Maximum plasma drug concentration at steady state                                                                 |
| CrCL        | Creatinine clearance                                                                                              |
| CrCLN       | Creatinine clearance normalized by body surface area                                                              |
| CSR         | Clinical study report                                                                                             |
| cSSTI       | Complicated skin and soft tissue infections                                                                       |
| EOIV        | End of IV study drug                                                                                              |
| EOT         | End of treatment                                                                                                  |
| IV          | Intravenous                                                                                                       |
| ME          | Microbiologically evaluable                                                                                       |
| MIC         | Minimum inhibitory concentration                                                                                  |
| MITT        | Modified intent-to-treat                                                                                          |
| mMITT       | Microbiological modified intent-to-treat                                                                          |
| PIL         | Patient information leaflet                                                                                       |
| PIP         | Paediatric Investigation Plan                                                                                     |

<div style=\"page-break-after: always\"></div>

| PK     | Pharmacokinetic(s)                 |
|--------|------------------------------------|
| PMA    | Post-menstrual age                 |
| PopPK  | Population pharmacokinetic(s)      |
| PTA    | Probability of target attainment   |
| q8h    | Every 8 hours                      |
| q12h   | Every 12 hours                     |
| SmPC   | Summary of Product Characteristics |
| TEAE   | Treatment emergent adverse event   |
| t1/2λz | Terminal half-life                 |
| tmax   | Time to maximum concentration      |
| TOC    | Test of cure                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 9 April 2015 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include new population, children over the age of 2 months and adolescents, for Zinforo; as a consequence, sections 4.1, 4.2, 5.2, 5.3 and 6.6 of the SmPC are updated with new information on dosing, pharmacokinetics and pre-clinical safety. The Package Leaflet is updated in accordance. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0074/2014 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0074/2014 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Greg Markey

Co-Rapporteur:

<div style=\"page-break-after: always\"></div>

N/A

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 9 April 2015      |
| Start of procedure:                                  | 27 June 2015      |
| CHMP Rapporteur Assessment Report                    | 7 August 2015     |
| CHMP members comments                                | 14 September 2015 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 15 September 2015 |
| Request for supplementary information (RSI)          | 24 September 2015 |
| CHMP Rapporteur Assessment Report                    | 19 November 2015  |
| CHMP members comments                                | 7 December 2015   |
| Request for supplementary information (RSI)          | 17 December 2015  |
| CHMP Rapporteur Assessment Report                    | 21 March 2016     |
| CHMP members comments                                | 18 April 2016     |
| Updated CHMP Rapporteur Assessment Report            | 21 April 2016     |
| Opinion                                              | 28 April 2016     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Zinforo (ceftaroline fosamil) is an oxyimino cephalosporin antibacterial agent for intravenous administration,  presented  for  clinical  use  as  the  more  water  soluble  N-phosphono  (fosamil),  which  is rapidly converted to ceftaroline by phosphatases in human plasma.

It was approved in the EU in August 2012 for treatment of adults with complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP). The recommended adult dosing regimen is 600  mg  (reduced  to  400  mg  for  patients  with  creatinine  clearance  [CrCL]  &gt;30  to ≤ 50  mL/min) administered as a 60-minute infusion every 12 hours (q12h) for 5 to 14 days for cSSTI and 5 to 7 days for CAP. In 2014 a Type II variation added dosage adjustment recommendations for adults with severe renal impairment (CrCL ≤ 30 mL/min) and end-stage renal disease (ESRD; CrCL &lt;15 mL/min), including patients undergoing haemodialysis.

The main purpose of this extension of indication application is to extend the use of Zinforo to children aged from 2 months to 17 years based on submission of the CSRs for the following studies, which were conducted in children (aged from 2 months to less than 18 years), in accordance with the agreed PIP:

- D3720c00004 (P903-23) A multicentre, randomized, observer-blinded, active-controlled study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of ceftaroline versus comparator in paediatric subjects with acute bacterial skin and skin structure infections
- D3720c00007 (P903-31) A multicentre, randomized, observer blinded, active-controlled study evaluating the safety, tolerability, pharmacokinetics, and efficacy of ceftaroline versus ceftriaxone in paediatric subjects with community-acquired bacterial pneumonia requiring hospitalization
- D3720c00013 (P903-24) A multicentre, randomized, observer-blinded, active-controlled study evaluating the safety, tolerability, pharmacokinetics, and efficacy of ceftaroline versus ceftriaxone plus vancomycin in paediatric subjects with complicated community-acquired bacterial pneumonia

The initial proposals for doses in children ages &gt; 2 months and adolescents &lt; 18 years were as follows:

| Infection   | Age/weight range        | Dose     | Frequency     |   Infusion time (minutes) | Recommended duration of antimicrobial treatment   |
|-------------|-------------------------|----------|---------------|---------------------------|---------------------------------------------------|
| cSSTI       | 2 months to < 24 months | 8 mg/kg  | every 8 hours |                        60 | 5-14 days                                         |
|             | ≥ 24 months (≤ 33 kg)   | 12mg/kg  | every 8 hours |                        60 | 5-14 days                                         |
|             | ≥ 24 months (> 33 kg)   | 400 mg   | every 8 hours |                        60 | 5-14 days                                         |
| CAP         | > 2 to < 24 months      | 8 mg/kg  | every 8 hours |                        60 | 5-7 days                                          |
|             | ≥ 24 months (≤ 33 kg)   | 12 mg/kg | every 8 hours |                        60 | 5-7 days                                          |
|             | ≥ 24 months (> 33 kg)   | 400 mg   | every 8 hours |                        60 | 5-7 days                                          |

<div style=\"page-break-after: always\"></div>

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

Additional toxicity studies using ceftaroline fosamil were conducted in juvenile rats to support this submission as follows:

| Study type and duration                                       | Routeof administration   | Species   | Studynumber (referencenumber)   | GLP compliant   |
|---------------------------------------------------------------|--------------------------|-----------|---------------------------------|-----------------|
| Dose range finding Juvenile toxicity /inneonatalrats/ 14 days | Intravenous              | Rat       | 20011802 (3011LR)               | No              |
| Juvenile toxicity in neonatal rats /14 days                   | 1Intravenous             | Rat       | 20011803 (3012LR)               | Yes             |

The MAH also updated the in-vitro susceptibility data.

## 2.2.2. Pharmacology

The in  vitro activity  of  ceftaroline  has  been  reported  against  clinically  important  community-acquired pneumonia  (CAP)  and  complicated  skin  and  soft  tissue  (cSSTI)  pathogens,  relevant  to  the  Zinforo prescribing information.

Ceftaroline activity was assessed against Gram-positive and Gram-negative bacteria isolated from adult and paediatric infected patients. Overall, susceptibility to ceftaroline was similar between isolates from paediatric  and  adult  age  groups  for  the  relevant  pathogens  causing  skin  and  respiratory  infections. However, susceptibility varied ±1 doubling dilution in the MIC90 values for S. aureus (MRSA) depending on the geographic region. MRSA isolates from children were generally more susceptible to ceftaroline than adult isolates by one doubling dilution.

The fastidious Gram-positive ( S. pneumoniae , β-haemolytic streptococci) and Gram-negative ( Haemophilus species) isolates obtained from both age groups were highly susceptible to ceftaroline when assessed using established interpretative criteria on susceptibility.

Against Enterobacteriaceae ceftaroline  is  active  only  against  non-ESBL-producing  strains.  Isolates  from adult and paediatric patients showed comparable susceptibilities across different geographic regions.

The  MAH  concluded  that  ceftaroline  is  equally  active  against  adult  and  paediatric  isolates  that  are clinically important in the two indicated infection types. CHMP agreed to this conclusion.

## 2.2.3. Pharmacokinetics

The  originally  intended  doses  of  ceftaroline  fosamil  proposed  by  the  MAH  in  paediatric  patients  with normal  renal  function  and  mild  renal  impairment  are  12  mg/kg  (up  to  a  maximum  dose  of  400  mg) administered every 8 hours as a 1 hour infusion to paediatric patients ≥2 years and 8 mg/kg ceftaroline fosamil every 8 hours as a 1 hour infusion in children 2 months to &lt;2 years.

Ceftaroline fosamil was given to male and female neonatal rats by slow intravenous bolus dose for 14 days from PND 7 to 21. Ceftaroline fosamil was well tolerated, no new target organs were identified and the NOAEL was the highest dose tested (270 mg/kg).

<div style=\"page-break-after: always\"></div>

Exposure levels (AUC(0-t)) of ceftaroline tested in the juvenile rat at 270 mg/kg/day were approximately 2  to  3-fold  higher  than  the  predicted  median  steady  state  AUC(0-24)  values  of  ceftaroline  (based  on simulations) in patients with mild renal impairment.

The  maximum  plasma  levels  of  ceftaroline  tested in the juvenile  rat  at  270  mg/kg/day  were approximately 20 to 28-fold higher than the predicted median steady state Cmax values of ceftaroline (based on simulations) in patients with mild renal impairment.

## 2.2.4. Toxicology

## Other toxicity studies

Ceftaroline  Fosamil:  14  day  intravenous  dose  range  finding  toxicity  study  in  the  neonatal  rat  (study number: 20011802 (3011LR)).

Ceftaroline fosamil was administered once daily to neonatal Sprague-Dawley rat pups (Crl:CD[SD]) from Post Natal Day (PND) 7 to 21 via an intravenous (bolus) injection (lateral tail vein) at 0, 30, 90 or 270 mg/kg to groups of 4 males and 4 females (main study) and 24 males and 24 females (toxicokinetic [TK] study)  (20011802  (3011LR)).  Controls  were  given  39.5  mg/mL  of  L-Arginine  in  0.9%  (w/v)  Sodium Chloride for Injection. Dams were not given the test or control articles. Clinical signs, body weights, body weight changes, urine analysis, toxicokinetic parameters (ceftaroline ceftaroline fosamil, or ceftaroline M1 metabolite [primary inactive metabolite]), organ weights, and gross and microscopic observations were measured/conducted.

There were no test article-related clinical  signs,  however  injection  site  reactions  occurred  at  all  doses, including  controls.  Body  weights  and  body  weight  gains  were  not  affected  at  any  dose.  Urine  analysis parameters  were  comparable  among  the  doses.  There  were  no  test  article-related  gross  lesions  or microscopic  findings,  or  any  changes  in  organ  weights  at  any  dose  that  were  considered  related  to ceftaroline fosamil (brain, paired kidneys and spleen).

Table 1 Summary of ceftaroline fosamil and M1 TK Results

| CeftarolineFosamil   | CeftarolineFosamil   | CeftarolineFosamil   | CeftarolineFosamil   | CeftarolineFosamil   |
|----------------------|----------------------|----------------------|----------------------|----------------------|
| Dose mg/kg/day       | Day                  | Tmax (h)             | Cmax (ng/mL)         | AUC(o-) (ng.h/mL)    |
| 30                   | PND 7                | 0.083                | 5620                 | 1420                 |
| 30                   | PND21                | 0.083                | 1450                 | 60.2                 |
| 90                   | PND7                 | 0.5                  | 1220                 | 254                  |
| 90                   | PND21                | 0.083                | 7870                 | 327                  |
| 270                  | PND 7                | 0.5                  | 7500                 | 5320                 |
| 270                  | PND21                | 0.5                  | 68.2                 | 320                  |
| Ceftaroline          | Ceftaroline          | Ceftaroline          | Ceftaroline          | Ceftaroline          |
| Dose mg/kg/day       | Day                  | Tmax (h)             | Cmax(ng/mL)          | AUC(o-)(ng.h/mL)     |
| 30                   | PND 7                | 0.083                | 35000                | 00966                |
| 30                   | PND21                | 0.083                | 73400                | 46200                |
| 90                   | PND 7                | 0.083                | 107000               | 251000               |
| 90                   | PND21                | 0.083                | 229000               | 134000               |
| 270                  | PND 7                | 0.083                | 370000               | 902000               |
| 270                  | PND21                | 0.083                | 829000               | 436000               |
| M-1 metabolite       | M-1 metabolite       | M-1 metabolite       | M-1 metabolite       | M-1 metabolite       |
| Dose mg/kg/day       | Day                  | Tmax (h)             | Cmax (ng/mL)         | AUC(o-) (ng.h/mL)    |
| 30                   | PND 7                | 1.5                  | 2550                 | 16400                |
| 30                   | PND21                | 0.5                  | 6860                 | 12100                |
| 90                   | PND 7                | 1.5                  | 6040                 | 52300                |
| 90                   | PND21                | 0.5                  | 18500                | 37200                |
| 270                  | PND7                 | 0.5                  | 21400                | 158000               |

<div style=\"page-break-after: always\"></div>

## Table 2 Summary of TK Results in Combined Male and Female

## Ceftaroline Fosamil: 14 day intravenous toxicity study in the neonatal rats with a 4-week recovery period (20011803 (3012LR)).

Ceftaroline fosamil was given once daily to neonatal Sprague-Dawley (Crl:CD[SD]) rat pups from PND 7 to 21 via an intravenous (bolus) injection (lateral tail vein) at 30, 90 or 270 mg/kg to groups of 20 males and  20  females  (main  and  recovery  study)  and  36  males  and  36  females  (toxicokinetic  [TK]  study) (20011803 (3012LR)). Controls were given 35.5 mg/mL of L-arginine in 0.9% (w/v) sodium chloride for injection.

Dams  were  not  dosed  during  this  study,  clinical  signs,  body  weight,  body  weight  changes,  functional observational  battery  (FOB),  urine  analysis,  haematology,  clinical  chemistry,  organ  weights,  and  gross and microscopic observations were investigated.

There were no test article-related deaths during this study. Morbidity and/or mortality occurred in 7 rats (3 main and 4 satellites). The premature decedents occurred in the control group and at 30 and 90 mg/kg (2, 3 and 2 rats respectively). In these seven animals, four were related to an injury (i.e., broken limb at 30 mg/kg, laceration on the chest at 30 mg/kg, laceration on the back at 0 mg/kg, or desheathing of the tail at 90 mg/kg), one was considered secondary to the intravenous dosing procedure (i.e., an embolism in the lungs), and two (one at 0 mg/kg and one at 30 mg/kg) had no known cause of death. All other animals survived to scheduled euthanasia on PND 22 (end of dose period) or PND 50 (end of recovery period).

Injection  site  reactions  (swelling,  discoloration  or  ulceration)  were  seen  at  all  doses,  including  the controls; however, these injection site reactions were attributed to the route of administration. At the end of the dosing and recovery periods, body weight gains in both sexes were comparable with controls.

There  were  no  test  article-related  effects  on  clinical  pathology  parameters  (haematology  and  urine analysis) at the end of the dosing or recovery periods. There were no test article-related effects on organ weights (brain, paired kidneys and spleen) at the end of the dosing and recovery periods.  There was an equivocal  test  article-related  increase  in  the  incidence  of  cysts/pitted  surfaces  of  the  kidneys  in  both sexes at PND 50.

Cysts were lined by a single layer of epithelium with a lumen size at least the diameter of two tubules in the region and involved a small area of the kidney. Minimal fibrosis occasionally encircled the cysts and, because of its focal nature, was considered not to be of toxicological concern.

<div style=\"page-break-after: always\"></div>

Table 3 Summary of Microscopic Findings (PND 22)

|                     | Males   | Males   | Males   | Males   | Females   | Females   | Females   | Females   |
|---------------------|---------|---------|---------|---------|-----------|-----------|-----------|-----------|
| Group               | 1       | 2       | 3       | 4       | 1         | 2         | 3         | 4         |
| Dose(mg/kg)         | 0       | 30      | 90      | 270     | 0         | 30        | 90        | 270       |
| No.ratsexamined     | 10      | 10      | 10      | 10      | 10        | 10        | 10        | 10        |
| Kidney(No.Examined) | 10      | 10      | 10      | 10      | 10        | 10        | 10        | 10        |
| Cyst                | (2)²    | (2)     | (7)     | (5)     | (5)       | (4)       | (5)       | (4)       |
| Fibrosis            | (0)     | (0)     | (1)     | (0)     | (2)       | (1)       | (0)       | (0)       |
| Minimal             | 0       | 0       | 1       | 0       | 2         | 1         | 0         | 0         |

Numbersinparenthesesrepresent thenumberofratswith thefinding,andnumberswithoutparentheses representthenumberofanimalswith aminimalgradeoffibrosis.

Microscopic findings in the kidney, observed at the end of the recovery period (PND 50), were similar in appearance to those observed at PND 22 (i.e., renal cyst with occasional minimal fibrosis).

Table 4 Summary of Microscopic Findings (PND 50)

<!-- image -->

|                     | Males   | Males   | Males   | Males   | Females   | Females   | Females   | Females   |
|---------------------|---------|---------|---------|---------|-----------|-----------|-----------|-----------|
| Group               | 1       | 2       | 3       | 4       | 1         | 2         | 3         | 4         |
| Dose(mg/kg)         | 0       | 30      | 90      | 270     | 0         | 30        | 90        | 270       |
| No.ratsexamined     | 9       | 10      | 9       | 10      | 9         | 10        | 10        | 10        |
| Kidney(No.Examined) | 9       | 10      | 9       | 10      | 9         | 10        | 10        | 10        |
| Cyst                | (2)     | (4)     | (5)     | (7)     | (2)       | (3)       | (3)       | (         |
| Fibrosis            | (0)     | (0)     | (3)     | (4)     | (0)       | (1)       | (3)       | (4)       |
| Minimal             | 0       | 0       | 3       | 4       | 0         | 1         | 3         | 4         |

Numbersinparenthesesrepresent thenumber of animalswith thefinding.andnumberswithoutparentheses represent thenumberofanimalswith aminimalgradeoffibrosis.

An increased macroscopic incidence of kidneys with cysts or pitted surfaces was observed at the end of the  recovery  period  (PND  50)  in  both  sexes  at  all  doses  (when  compared  to  published  background macroscopic and microscopic renal findings in Sprague-Dawley rats).

The MAH stated that as microscopic assessment is considered to provide a more accurate assessment of cyst  incidence  and  relationship  to  test  article  administration,  the  microscopic  findings  more  accurately reflected the true incidence of this finding.

Microscopically, an increased and variable incidence of renal cysts was present at all doses at PND 22 and PND 55 in rats, including controls (Owen et al 1986) The incidence was also increased when compared to a recent histological review of renal cysts in 45 day old control Sprague Dawley rats (McKay 2012) which revealed an overall incidence of renal cysts of less than 10%. This observation may suggest a possible procedural-related  effect  in  the  current  study.  This  is  supported  by  current  literature  in  which  it  is suggested  that  glucocorticoids  play  a  key  role  in  nephrogenesis  in  young  rodents  and  that  excess corticosteroids can potentially lead to cystogenesis (McDonald et al., 2011, Gupta et al., 2001, Chan et al., 2010).

The  juvenile  rats  in  this  study  were  being  dosed  during  a  time  period  which  coincides  with  active nephrogenesis  (PND  1  to  PND  11)  (Zoetis et  al .,  2003)  and  so  a  potential  stress-associated  effect  on tubule development, secondary to the intravenous dosing procedure should be considered. An additional consideration is that all animals received a high volume daily bolus injection of ceftaroline fosamil or the control article. This could also cause altered electrolyte and fluid homeostasis in the kidney and contribute to  renal  tubule  dilatation  and  cyst  formation.  This  phenomenon  has  been  described  in  the  beagle  dog following administration of high oral doses of potent diuretics.

This finding did not fully correlate with the microscopic findings as cysts were also identified histologically in  control rats.  The MAH explained that as these findings involved only a small portion of the kidney, were present in control, and occurred in the absence of significant changes in renal function or urinary parameters, they were considered not to be adverse.

<div style=\"page-break-after: always\"></div>

At the end of the recovery period (PND 50) there was an increase in the incidence of cysts at all doses in males and at 270 mg/kg/day in females. This was accompanied by an increased incidence of pericystic fibrosis at 90 and 270 mg/kg/day (both sexes).

When the males were evaluated on PND 50, the maximum and average values recorded in the forelimb grip  test  were  decreased  at  270  mg/kg.  Conversely,  in  females,  increased  maximum  (p≤0.05)  and average values were recorded in the fore- and hind limb grip tests in this same dose group on PND 50. The differences observed in these tests were considered incidental, and not related to the test article as: 1) alterations in movement were not observed in these rats; and 2) opposing observations occurred in males (i.e., decrease in grip strength) and females (i.e., increase in grip strength). There were no other test article-related effects on neurobehavioral endpoints.

A significant elevation (p ≤ 0.05) of blood urea nitrogen (BUN) was observed on PND 22 in males at 270 mg/kg.  As  individual  variation  was  large  and  there  was  no  correlation  of  higher  values  with  cyst occurrence, this was considered not to be of toxicological significance. There were no other test articlerelated effects on clinical chemistry endpoints.

The No Observed Adverse Effect Level (NOAEL) was considered to be 270 mg/kg in juvenile, suckling rats.

Table 5 Summary of ceftaroline fosamil and M1 TK Results

| CeftarolineFosamil   | CeftarolineFosamil   | CeftarolineFosamil   | CeftarolineFosamil   | CeftarolineFosamil   |
|----------------------|----------------------|----------------------|----------------------|----------------------|
| Dose mg/kg/day       | Day                  | Tmax (h)             | Cmax(ng/mL)          | AUC(o-9) (ng.h/mL)   |
| 30                   | PND 7                | NR                   | NR                   | NR                   |
| 30                   | PND21                | 0.083                | 7800                 | 3140                 |
| 90                   | PND 7                | NR                   | NR                   | NR                   |
| 90                   | PND21                | NR                   | NR                   | NR                   |
| 270                  | PND 7                | NR                   | NR                   | NR                   |
| 270                  | PND21                | NR                   | NR                   | NR                   |
| Ceftaroline          | Ceftaroline          | Ceftaroline          | Ceftaroline          | Ceftaroline          |
| Dose mg/kg/day       | Day                  | Tmax (h)             | Cmax(ng/mL)          | AUC(o-) (ng.h/mL)    |
| 30                   | PND 7                | 0.083                | 49600                | 92500                |
| 30                   | PND21                | 0.083                | 85900                | 71800                |
| 90                   | PND 7                | 0.5                  | 131000               | 325000               |
| 90                   | PND21                | 0.083                | 201000               | 140000               |
| 270                  | PND 7                | 0.083                | 323000               | 1020000              |
| 270                  | PND21                | 0.083                | 571000               | 419000               |
| MI-1metabolite       | MI-1metabolite       | MI-1metabolite       | MI-1metabolite       | MI-1metabolite       |
| Dose mg/kg/day       | Day                  | Tma (b)              | Cmax(ng/mL)          | AUC(o-9 (ng.h/mL)    |
| 30                   | PND 7                | 4                    | 1820                 | 14300                |
| 30                   | PND21                | 0.5                  | 6090                 | 10700                |
| 90                   | PND 7                | 1.5                  | 8180                 | 47500                |
| 90                   | PND21                | 0.5                  | 17300                | 28400                |
| 270                  | PND 7                | 1.5                  | 19200                | 156000               |
| 270                  | PND21                | 0.5                  | 41100                | 73300                |

NR: No result as long term stability of 28 days was exceeded.

## 2.2.5. Ecotoxicity/environmental risk assessment

The  updated  data  submitted  in  this  application  do  not  lead  to  a  significant  increase  in  environmental exposure further to the use of Zinforo.

Considering the above data, CHMP agreed that Zinforo is not expected to pose a risk to the environment.

## 2.2.6. Discussion on non-clinical aspects

## Assessment of paediatric data on non-clinical aspects

Exposure levels (AUC(0-t)) of ceftaroline tested in the juvenile rat at 270 mg/kg/day were approximately 2  to  3-fold  higher  than  the  predicted  median  steady  state  AUC(0-24)  values  of  ceftaroline  (based  on

<div style=\"page-break-after: always\"></div>

simulations) in paediatric patients with mild renal impairment. The maximum plasma levels of ceftaroline tested in the juvenile rat at 270 mg/kg/day were approximately 20 to 28-fold higher than the predicted median steady state Cmax values of ceftaroline (based on simulations) in paediatric patients with mild renal impairment.

Table 6: Median (90% PI) ceftaroline steady-state CmaxSS and AUC24SS, by age following the proposed dose for subjects aged from 6 to &lt;24 months in paediatric patients with either normal renal function, or mild renal impairment based on simulations.

| AGE                                              | Weight (kg)                                      | CmaxSS (mg/L)                                    | AUC24SS (mg*hr/L)                                | Dose*                                            |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Adults 600 mg q12h 1 hr                          | 77.6 (52.5,105)                                  | 21.0 (11.9,36.5)                                 | 97.3 (59.1,164)                                  | 600 mg                                           |
| Normal renal function (CrCL >80ml/min)           | Normal renal function (CrCL >80ml/min)           | Normal renal function (CrCL >80ml/min)           | Normal renal function (CrCL >80ml/min)           | Normal renal function (CrCL >80ml/min)           |
| 12- < 18 years                                   | 52.9 (36.8,75.3)                                 | 19.7 (11.0,34.2)                                 | 122 (72.7,201)                                   | 12 mg/kg (max of 400 mg)                         |
| 6- < 12 years                                    | 28.5 (19.3,46.5)                                 | 27.6 (16.4,43.3)                                 | 157 (99.7,245)                                   | 12 mg/kg (max of 400 mg)                         |
| 2- < 6 years                                     | 15.8 (11.8,22.2)                                 | 27.1 (16.8,41.8)                                 | 144 (92.6,225)                                   | 12 mg/kg (max of 400 mg)                         |
| 18- < 24 months                                  | 11.7 (9.8,14.1)                                  | 18.8 (11.8,29.1)                                 | 107 (69.0,165)                                   | 8 mg/kg (max of 400 mg)                          |
| 12- < 18 months                                  | 10.4 (8.6,12.7)                                  | 19.1 (11.9,29.4)                                 | 113 (71.8,174)                                   | 8 mg/kg (max of 400 mg)                          |
| 6- < 12 months                                   | 8.43 (6.55,10.7)                                 | 19.6 (12.2,30.0)                                 | 120 (78.3,188)                                   | 8 mg/kg (max of 400 mg)                          |
| 2- < 6 months                                    | 5.75 (4.12,7.66)                                 | 19.2 (12.1,29.7)                                 | 134 (86.6,208)                                   | 8 mg/kg (max of 400 mg)                          |
| Mild renal impairment (>50ml/min CrCL < 80ml/min | Mild renal impairment (>50ml/min CrCL < 80ml/min | Mild renal impairment (>50ml/min CrCL < 80ml/min | Mild renal impairment (>50ml/min CrCL < 80ml/min | Mild renal impairment (>50ml/min CrCL < 80ml/min |
| Adults 600 mg q12h 1 hr                          | 77.6 (52.2,105)                                  | 20.9 (11.7,36.6)                                 | 97.1 (58.8,164)                                  | 600 mg                                           |
| 12- < 18 years                                   | 52.7 (36.7,74.7)                                 | 20.7 (11.5,35.6)                                 | 136 (80.9,227)                                   | 12 mg/kg (max of 400 mg)                         |
| 6- < 12 years                                    | 28.6 (19.2,46.8)                                 | 28.8 (17.0,45.4)                                 | 175 (110,276)                                    | 12 mg/kg (max of 400 mg)                         |
| 2- < 6 years                                     | 15.8 (11.8,22.4)                                 | 28.3 (17.5,44.0)                                 | 160 (102,252)                                    | 12 mg/kg (max of 400 mg)                         |
| 18- < 24 months                                  | 11.7 (9.8,14.1)                                  | 20.6 (12.8,32.3)                                 | 133 (82.7,219)                                   | 8 mg/kg (max of 400 mg)                          |

<div style=\"page-break-after: always\"></div>

| 12- < 18 months   | 10.4 (8.6,12.7)   | 20.9 (13.0,32.6)   | 140 (86.0,227)   | 8 mg/kg (max of 400 mg)   |
|-------------------|-------------------|--------------------|------------------|---------------------------|
| 6- < 12 months    | 8.43 (6.55,10.7)  | 21.4 (13.3,33.3)   | 152 (92.6,247)   | 8 mg/kg (max of 400 mg)   |
| 2- < 6 months     | 5.75 (4.11,7.67)  | 21.2 (13.2,33.3)   | 168 (103,275)    | 8 mg/kg (max of 400 mg)   |

Median (5th, 95th percentile) based on summary of 100 trials and corresponds to median (90% PI). Adult dose and regimen is listed in first row of column 1. *Paediatric dose administered q8h as 1 hour infusion. Abbreviations: AUC24SS area under the concentration-time curve over 24 hours at steady-state; CmaxSS maximum concentration for a dosing interval at steady-state; PI prediction interval; q12h every 12 hours.

To describe the juvenile toxicity data, CHMP asked the MAH to include the following wording in section 5.3 of the Zinforo SmPC:

Juvenile toxicity Intravenous bolus dosing of ceftaroline fosamil to suckling rats from post-natal day 7 to 20 was well tolerated at plasma exposures approximately 2-fold higher than those for paediatric patients. Renal cortical cysts were observed in all groups, including controls, on PND50. The cysts involved a small portion of the kidney and occurred in the absence of significant changes in either renal function or urinary parameters. Therefore, these findings were not considered to be adverse.

## 2.2.7. Conclusion on the non-clinical aspects

Two juvenile toxicity rat studies were conducted in support of the use of Zinforo in paediatric patients aged  from  2  months  to  &lt;18  years  with  CAP  or  cSSTI.    In  the  non-GLP  dose  range  finding  study ceftaroline fosamil was given once daily to neonatal Sprague-Dawley rat pups from Post Natal Day (PND) 7 to 21 via an intravenous (bolus) injection (lateral tail vein) at 0, 30, 90 or 270 mg/kg. In this study ceftaroline fosamil was well tolerated and did not result in any mortality or clinical signs. There were no apparent changes in body weight, body weight gains, organ weights (brain, paired kidneys and spleen) or urine analysis parameters. There were no gross and microscopic finding considered related to ceftaroline fosamil at any dose.

Ceftaroline fosamil was given once daily to neonatal Sprague-Dawley (Crl:CD[SD]) rat pups from PND 7 to 21 via an intravenous (bolus) injection (lateral tail vein) at 30, 90 or 270 mg/kg (GLP study). Transient reductions  in  body  weight  gains  occurred  in  both  sexes  at  all  doses  at  the  start  of  the  dosing  period; however, these reductions did not persist. At the end of study, there were no relevant test article-related effects on clinical signs, body weight, neurobehavioral parameters, clinical pathology parameters or organ weights.

Exposure levels (AUC0-t) of ceftaroline tested in the juvenile rat at 270 mg/kg/day were approximately 2 to  3-fold  higher  than  the  predicted  median  steady  state  AUC(0-24)  values  of  ceftaroline  (based  on simulations) in paediatric patients with mild renal impairment. The maximum plasma levels of ceftaroline tested in the juvenile rat at 270 mg/kg/day were approximately 20 to 28-fold higher than the predicted median  steady  state  Cmax  values  of  ceftaroline  (based  on  simulations).  Exposures  at  30  and  90 mg/kg/day were at or below the predicted clinical exposures.

There were observations of microscopic renal cysts in male rats at 90 mg/kg (PND 22) and in both sexes at (PND 55) there were considered possibly test article-related, but not adverse, due to the small area involved,  presence  in  control,  normal  morphology  of  the  overall  kidney,  and  lack  of  changes  in  renal function or urine parameters. Based on the results of this study, 270 mg/kg is considered to be the No Observed Adverse Effect Level (NOAEL).

<div style=\"page-break-after: always\"></div>

However at the end of the recovery period (PND 50) there was an increase in the incidence of cysts at all doses in males and at 270 mg/kg/day in females. This was accompanied by an increased incidence of pericystic  fibrosis  at  90  and  270  mg/kg/day  (both  sexes).  This  could  indicate  a  progression  of  these effects, which were not present in the controls and therefore cannot be attributed to procedural factors. Considering that the kidney has been identified as the primary target organ of toxicity in adult rats and monkeys, and that the extension of the indication sought includes very young children (from 2 months of age), the MAH was asked to provide a more extensive discussion concerning the renal findings in juvenile rats, to justify the conclusion that these findings are not adverse.

The MAH responded to this issue and clarified that overall, as the cysts involved only a small area of the kidney and the fibrosis was focal and minimal in nature and both occurred in the absence of significant changes in renal function or urinary parameters, did not appear to have any significant implications for the  animals  (no  adverse  clinical  signs,  only  transient  effects  on  body  weight  gain  and  no  significant changes  in  clinical  pathology  or  organ  weights)  they  are  considered  not  to  be  adverse.  Based  on  the above analysis the MAH's proposal for the additional text in Section 5.3 of the SmPC was accepted by CHMP.

The  updated  data  submitted  in  this  application  do  not  lead  to  a  significant  increase  in  environmental exposure further to the use of Zinforo. Considering the available data, Zinforo is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.3.2. Pharmacokinetics

## Special populations

The details of the two prior PK studies in patients aged &lt; 18 years are provided, so that all the relevant data are made available for review.

Previously reported studies:

P903-15 was included in the initial application dossier for ceftaroline even though use below 18 years of age was not sought at that time. This study planned to evaluate safety and PK in patients aged from 12 to 17 years who were to receive a single dose of 8 mg/kg if &lt; 75 kg or 600 mg if ≥75 kg while being hospitalised and treated with licensed antibacterial agents for infections of any type.

P903-21 was  submitted  and  assessed  as  part  of  variation  II/08  in  2013,  which  did  not  lead  to  any changes in the Zinforo SmPC. The study evaluated the pharmacokinetics and safety of a single dose of ceftaroline in children from birth to &lt; 12 years of age. This was an open-label, sequential, single dose study in children while being hospitalised and treated with licensed antibacterial agents for infections of any type. The study enrolled 5 cohorts who were dosed as follows:

- o Cohort 1 - 6 to &lt;12 years (n=10); 10 mg/kg (max 600 mg) as a 1 hour infusion
- o Cohort 2 - 2 to &lt;6 years (n=8); 15 mg/kg as a 1.5 hour infusion
- o Cohort 3 - 28 days to &lt;2 years with equal numbers &lt; or &gt; 12 months (n=12); 12 mg/kg as a 1 hour infusion if ≥5 months and 8 mg/kg as a 1 hour infusion if ≥28 days to &lt;5 months
- o Cohort  4  -  full-term  neonates  aged  &lt;28  days  with  equal  numbers  &lt;  or  &gt;  14  days  (n=12);  8 mg/kg as a 1 hour infusion
- o Cohort 5 - preterm neonates (gestational age 32 to 37 weeks) aged &lt;28 days with 5 older than 14 days and 6 younger than 14 days (n=11); 8 mg/kg as a 1 hour infusion

Plasma  concentrations of ceftaroline, ceftaroline fosamil (prodrug) and  ceftaroline M-1  (inactive metabolite) were determined in samples obtained at end of infusion and then at 15 to 45 minutes, 3 to 4 h and 5 to 7 h from the end of infusion.

## New studies:

The study designs for studies P903-23, P903-24 and P903-31 are described in the clinical efficacy section. In  each CSR there is a bioanalytical report on the assay performance and the individual concentration

<div style=\"page-break-after: always\"></div>

data are listed for ceftaroline, ceftaroline fosamil and the open ring form (M-1). Due to sparse sampling, the data were included in the POPPK and PK-PD analyses and not analysed separately.

## D3720c00004 (P903-23) acute bacterial skin and skin structure infections

Sparse  PK  blood  sampling  (2  samples  of  no  more  than  2  mL/kg  per  patient)  was  performed  only  at selected study centres, and for only those patients that consented to PK evaluation and were randomized to ceftaroline fosamil. A total of 198 plasma samples from 99 patients in the ceftaroline treatment group were analysed.

## D3720c00007 (P903-31) community-acquired bacterial pneumonia requiring hospitalization

Sparse PK blood sampling was conducted as above.

## D3720c00013 (P903-24) complicated community-acquired bacterial pneumonia

Sparse PK blood sampling was conducted as above.

## Dose selection for P903-23, P903-31 and P903-24:

The  POPPK  models  for  ceftaroline  fosamil  and  ceftaroline  from  the  original  MAA  were  updated  to incorporate data in adolescents (12 to &lt;18 years) from P903-15 and to include allometric scaling of PK parameters by weight for children. Data from several additional studies in adults were added to the model and the dose range was limited to 250 mg to 1000 mg.

The  initial  POPPK  model  comprised  11  Phase  1  studies  in  healthy  volunteers,  4  Phase  2/3  studies  in patients with cSSTI and 2 Phase 3 studies in patients with CAP. Interim PK data from P903-21 were then added and the final POPPK model consisted of a simultaneous two-compartment disposition model for the prodrug ceftaroline fosamil and a two-compartment disposition model for ceftaroline.

As  in  the  previous  model  the  variability  in  clearance  was  primarily  predicted  by  creatinine  clearance (normalized by BSA). The relationship between age and clearance was estimated and kept constant for children 2 to &lt;18 years of age. For children aged &lt; 2 years a published sigmoid hyperbolic model based on  post-menstrual  age  was  used  to  account  for  maturation  of  renal  function.  The  model  adequately predicted observed data in paediatric patients and adults.

The  model  was  then  used  to  simulate  a  range  of  dose  regimens  to  assess  steady-state  exposure measures (Cmax, AUC and % f T&gt;MIC) and make dose recommendations for the three new studies.

Three thousand patients (1000 per cohort) aged 2 to &lt;18 years and 3000 aged 28 days to &lt;24 months were simulated with a uniform distribution for each year of age for those 2 years and older or each month for those aged &lt;24 months. An equal number of males and females were simulated. Body weights for each simulated patient were predicted based on age in accordance with CDC growth charts. For children &lt;24 months, dosing scenarios with various infusion lengths (1, 1.5 and 2 h) and dose amounts (4, 6, 8, 10 and 12 mg/kg) were simulated. In all simulated scenarios, the dose was capped based on weight so that paediatric patients would not receive more than the currently approved adult dose per day (1200 mg/day).

For P903-23 and P903-31, the goal was to select doses to match or exceed the % f T&gt;MIC in adults dosed with ceftaroline fosamil 600 mg q12h without appreciably exceeding the Cmax and AUC in adults at this dose. For P903-24, which enrolled subjects with complicated CAP, the goal was to select doses to match or exceed the % f T&gt;MIC in adults dosed with ceftaroline fosamil 600 mg q8h. Based on the simulations, the following dose regimens were selected:

## P903-23 and P903-31:

<div style=\"page-break-after: always\"></div>

- 6 months to &lt;18 years: 12 mg/kg q8h as a 1 h infusion up to a maximum of 400 mg q8h for subjects weighing &gt;33 kg
- 2 months to &lt;6 months: 8 mg/kg q8h as a 1 h infusion

## P903-24:

- 6 months to &lt;18 years: 15 mg/kg q8h as a 2 h infusion up to a maximum of 600 mg q8h for subjects weighing &gt;40 kg
- 2 months to &lt;6 months: 10 mg/kg q8h as a 2 h infusion

## Results

## P903-15

The nine adolescents dosed in this study had a mean age of 13.7 years (range 12-16 years) and included 5 male and 4 female subjects. Mean BMI was 21.51 kg/m2 and mean CrCl was 156.84 mL/minute. The actual amount of ceftaroline administered ranged from 320 to 600 mg based on a weight range of 40.6 to 79.1 kg. Eight subjects received a complete single dose of ceftaroline fosamil while one refused further infusion  after  receiving  about  80%  (199  ml  and  406  mg)  of  the  planned  dose  of  510  mg  based  on  a weight of 64 kg) because of extravasation at the infusion site. The PK data are summarised in the table below:

Table 7: PK parameters (mean±SD) for ceftaroline, ceftaroline fosamil and ceftaroline M1 following a single intravenous dose of ceftaroline fosamil-PK population

| PKParameter                | Ceftaroline (N=8)a   | CeftarolineM-1 (N=8)   | CeftarolineFosamil (N=8)   |
|----------------------------|----------------------|------------------------|----------------------------|
| AUCo-t, ngoh/mL            | 38391.81 ± 16063.63  | 10355.04 ± 7799.51     | 2293.90 ± 2476.80          |
| AUCo., ngh/mL              | 38876.55 ± 16240.87  | 11186.77 ± 7830.76     | NC                         |
| Cmax, ng/mL                | 15276.14 ± 5996.84   | 2130.92 ± 2536.78      | 3272.51 ± 3378.25          |
| Tmax, hb                   | 0.95 (0.48-1.00)     | 1.15 (0.92-3.00)       | 0.50 (0.48-0.92)           |
| T, h                       | 1.94 ± 0.27          | 3.26± 0.55             | NC                         |
| CL, mL/h                   | 14045.58 ± 13409.84  | 44194.74 ± 16849.96    | NC                         |
| Vz, mL                     | 35572.84 ± 45126.16  | 217519.74 ± 94399.62   | NC                         |
| Vss. mL                    | 43091.61 ± 50837.89  | 214384.19 ± 89132.43   | NC                         |
| Aeo-t, mg                  | 211.71 ± 72.38       | 18.82 ± 8.48           | 0                          |
| Percent recovered (% dose) | 56.97 ± 18.23        | 5.00 ± 2.79            | 0                          |
| CL, mL/h                   | 8762.12± 10882.35    | 2003.12 ± 969.70       |                            |

One  patient  had  unusually  low  plasma  concentrations  of  ceftaroline  and  unusually  high  plasma concentrations of ceftaroline M-1.

For example, Cmax ceftaroline was only 18% and AUC0-∞ was only 14% compared to the mean values for the other subjects whereas AUC0-∞ ceftaroline M-1 was 3.5-times the mean for the others. Excluding data  from  this  patient  resulted  in  significantly  lower  standard  deviations  for  mean  PK  parameters  and gave higher mean Cmax and AUC0-∞ ceftaroline values (17031.49 ± 3632.80 ng/ml and 43569.02 ± 10110.04 ng·h/ml) compared to the table below. After exclusion of the data, the re-calculated mean T½ for ceftaroline was 1.86 ± 0.17 h and ~55% of the dose was excreted in urine.

The mean Cmax and AUC0-∞ for ceftaroline in these adolescents were about 10% and 23% less than the values  observed  in  adult  subjects  following  a  600  mg  dose  of  ceftaroline  fosamil  in  P903-01.  After exclusion of the subject with unusual PK ceftaroline the mean Cmax for ceftaroline M-1 was 1250.07 ±

<div style=\"page-break-after: always\"></div>

515.80 ng/ml (~ 7% Cmax ceftaroline) and the mean AUC0-∞ was 8466.58 ± 1574.58 ng·h/ml (~ 19% of the AUC0-∞ ceftaroline). The mean T½ for ceftaroline M-1 was 3.41 ± 0.39 h and approximately 4.4% of the dose was excreted in urine as ceftaroline M-1.

Ceftaroline fosamil was rapidly converted to ceftaroline and was generally only measurable in plasma for 0.25 to 1 h after the end of study drug infusion. The mean Cmax for ceftaroline fosamil was 3693.58 ± 3414.65  ng/ml  (~  22%  of  the  Cmax  for  ceftaroline)  and  the  mean  AUC0-t  was  2591.71  ±  2515.79 ng·h/ml (~ 6% of the AUC0-t for ceftaroline). Ceftaroline fosamil was not measurable in urine samples.

## P903-21

Ceftaroline was measurable in all PK samples and all patients had ceftaroline plasma concentrations &gt;1 μg/mL in samples collected 3 to 4 h after the end of the infusion. The majority (45/53) had &gt;1 μg/mL in samples collected 5 to 7 h after the end of infusion.

The mean end of infusion (Cmax) concentrations of ceftaroline were lower in Cohorts 4 and 5 than in Cohorts  1,  2,  or  3  but  the  lower  dose  may  not  fully  explain  the  lower  Cmax.  In  contrast,  mean concentrations at 5 to 7 h post-infusion were higher for Cohorts 4 and 5 compared with Cohorts 1, 2, and 3, which suggested slower clearance in the youngest groups consistent with immature renal function. In keeping  with  the  finding,  ceftaroline  plasma  concentrations  in  samples  collected  during  the  last  2  PK collection intervals tended to be higher in patients aged from birth to 14 days compared to those aged &gt;14 to &lt;28 days.

Table 8 Mean ceftaroline plasma concentrations by cohort

|                                  | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   |
|----------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| CollectionTimes                  | Cohort 1 (m =10)                                 | Cohort2 (m =8)                                   | Cohort3 (m = 12)                                 | Cohort4 (n = 12)                                 | Cohort5 (n = 11)                                 |
| Atendofinfusion (±5minutes)      | 18325.08± 3563.06                                | 23052.72± 5485.06                                | 16938.90± 3693.24                                | 10530.69± 2529.54                                | 11091.64± 1505.90                                |
| 15to45minutes fromendof infusion | 12114.21± 3157.54                                | 14860.30± 3448.84                                | 12549.92± 2861.96                                | 9782.58± 2013.87b                                | 10348.61± 1064.83a                               |
| 3to4hoursfrom endofinfusion      | 2769.49± 890.70                                  | 3626.51± 1663.57                                 | 3286.77± 1215.47                                 | 4600.61 ± 819.13                                 | 5061.97± 1668.45                                 |
| 5to7hoursfrom endofinfusion.     | 1138.30± 489.43                                  | 1600.83± 641.75                                  | 1573.37±688.59                                   | 2687.71± 623.84                                  | 3115.87± 1350.72                                 |

Notes:Cohort1:≥6yearsto&lt;12years;Cohort2:≥24monthsto&lt;6years;Cohort3:28daysto&lt;24months; Cohort4:term(gestationalage≥38weeks)neonates&lt;28days;Cohort5:preterm(gestationalage32-37weeks) neonates&lt;28days.

## Table 9 Mean ceftaroline plasma concentrations by age subgroup within cohorts 3,4 and 5

| Collection Times                   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   | Mean(±SD)CeftarolinePlasmaConcentration(ng/mL)   |
|------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Collection Times                   | Cohort3A (6 =u)                                  | Cohort3B (m = 3)                                 | Cohort4A (m =6)                                  | Cohort4B (n =6)                                  | Cohort5A (m=5)                                   | Cohort5B (n =6)                                  |
| At end of infusion(±5 minutes)     | 17574.86± 4089.45                                | 15031.02± 919.52                                 | 10808.87± 1995.66                                | 10252.51± 3147.78                                | 11168.62± 1599.434                               | 11030.05± 1614.37b                               |
| 15 to 45 minutesfrom endofinfusion | 13183.51± 3045.91                                | 10649.14 ± 844.47                                | 9746.93± 1379.36                                 | 9825.35± 2785.08b                                | 9848.78± 1535.71                                 | 10748.48± 221.83b                                |
| 3to4hours fromendof infusion       | 3440.01 ± 1360.72                                | 2827.07± 544.61                                  | 4280.58± 870.61                                  | 4920.64± 687.30                                  | 3807.40± 1293.25                                 | 6107.45± 1159.26                                 |
| 5to7hours fromendof infusion.      | 1626.06± 786.01                                  | 1415.30± 294.35                                  | 2314.60± 381.99                                  | 3060.82± 613.34                                  | 2340.73± 1008.17                                 | 3761.81± 1316.91                                 |

Notes:Cohortsubstrata:3A=5monthsto&lt;24months,administered12mg/kg;3B=28daysto&lt;5months administered8mg/kg;4A=term neonates&gt;14daysto&lt;28days,administered8mg/kg;4B=termneonates0 to 14days,administered8mg/kg;5A=pretermneonates&gt;14daysto&lt;28days,administered8mg/kg 5B=pretermneonates0to14days,administered8mg/kg.

<div style=\"page-break-after: always\"></div>

Ceftaroline fosamil plasma concentrations were variable and were typically only measurable at the end of the  infusion  or  within  15-45  min  post-infusion.  Eight  had  no  measurable  ceftaroline  fosamil  in  any samples but had ceftaroline and ceftaroline M-1 levels that were consistent with appropriate dosing.

The highest mean ceftaroline M-1 plasma concentration occurred in samples collected at 3 to 4 h postinfusion.  At  the  end  of  infusion,  mean  ceftaroline  M-1  plasma  concentrations  in  each  cohort  were approximately  3%  to  4%  of  mean  ceftaroline  plasma  concentrations  at  the  same  time.  For  plasma samples collected 5 to 7 h after the end of infusion, mean ceftaroline M-1 levels were 53.3%, 50.3%, 51.1%, 26.0% and 25.7% of mean ceftaroline levels at the same time for Cohorts 1-5, respectively.

## D3720c00004 (P903-23) acute bacterial skin and skin structure infections

A total of 198 plasma samples from 99 patients in the ceftaroline treatment group were analysed.

## D3720c00007 (P903-31) community-acquired bacterial pneumonia requiring hospitalization

A total of 228 plasma samples from 116 patients in the ceftaroline treatment group were analysed. There were 22 patients with samples taken near the end of a ceftaroline fosamil infusion in which concentrations of ceftaroline were above 30 mg/L, including 12 with 30-40 mg/L and a maximum level of 68.9 mg/L. These levels exceeded the upper limit of the 90% prediction interval for the expected maximum plasma concentration in adults dosed with 600 mg q12h. However, concentrations had decreased by 4 to 50-fold by the time of the next PK sample from the same patient (typically 3-4 hours later). Safety data from these patients did not show trends in AEs or in laboratory abnormalities. The MAH concluded that the high concentrations may reflect sampling from sites near the site of infusion (e.g. the same arm).

## D3720c00013 (P903-24) complicated community-acquired bacterial pneumonia

A total of 58 plasma samples from 29 patients in the ceftaroline treatment group were analysed.

## The MAH compiled the paediatric PK data to support modelling and simulations.

The application contained a POPPK report dated 2011, which included P903-15 but not the data from the sequential studies in children, and a PK-PD report dated January 2015. The former report ( CPT-MS-14 ) comprises the analyses reported above that were used to select the dose regimens for the three new paediatric studies. The latter report ( CPT-MS-08 ) is the most relevant to this extension of indication and included all the available paediatric data.

## Population PK modelling

After the completion of the three new studies the POPPK model for ceftaroline and ceftaroline fosamil was updated to include the new data and also the final data from P903-21.

- o The  resulting  ceftaroline  POPPK  dataset  comprised  525  patients  and  195  healthy  subjects  or subjects  with  various  degrees  of  renal  impairment  contributing  a  total  of  6633  measurable concentrations (1799 ceftaroline fosamil and 4834 ceftaroline).
- o Of the 525 patients 305 paediatric patients contributed a total of 974 measurable concentrations (234 ceftaroline fosamil and 740 ceftaroline).
- o Of these 305 patients, 42 were ≥12 to &lt;18 years of age, 74 were ≥6 to &lt;12 years, 102 were ≥2 to  &lt;6  years,  64  were  ≥24  days  and  &lt;2  years,  12  were  term  neonates  (gestational  age  ≥38 weeks, ages &lt;28 days) and 11 were preterm neonates (gestational age 32-37 weeks, ages &lt;28 days).
- o The paediatric population consisted of 173 males and 132 females with ages ranging from 1 day to 18 years and weights ranging from 1.5 to 100 kg. All (with one exception) had either normal renal function or mild renal impairment.

<div style=\"page-break-after: always\"></div>

Paediatric patients demonstrated similar PK for ceftaroline as adult patients after accounting for weight and  maturational  changes.  The  combined  ceftaroline  fosamil  and  ceftaroline  population  PK  model provided  a  good  description  of  the  observed  data.  Diagnostic  plots  stratified  by  age  group  and  study revealed that the model was consistent with the observed data and no systematic bias was evident. All paediatric age groups were adequately described by the model. This population PK model was used to generate individual predicted PK parameters for patients that had PK samples collected, as summarised in the tables below.

The  final  combined  POPPK  model  for  ceftaroline  fosamil  and  ceftaroline  was  used  to  simulate  plasma concentration-time  data  using  the  current  ceftaroline  dosing  regimen  for  adults  and  various  dosing regimens for paediatric patients (preterm neonates to &lt;18 years old) with normal renal function, or mild renal  impairment.  Concentration  data  were  simulated  at  steady-state.  Weights  for  the  paediatric  age groups were based on CDC Growth Charts. Covariates for the adult simulations were generated from a multivariate normal distribution based on the covariances observed in the POPPK data in patients.

Table 10 Median (90% confidence interval) ceftaroline PK parameters by cohort and dose based on individual population PK model-predicted parameters for study P90323

| Cohort (AgeRange)          | Dosea        |   nb | CL,L/h           | Cmax, μg/mL        | AUCo-24h.ss, μgoh/mL   | T,h              |
|----------------------------|--------------|------|------------------|--------------------|------------------------|------------------|
| Cohort1 (12to<18years)     | 12 mg/kg q8h |    1 | 2.47 (2.47-2.47) | 32.6 (32.59-32.59) | 292 (291.5-291.5)      | 2.16 (2.16-2.16) |
| Cohort1 (12to<18years)     | 400mg q8h    |   21 | 9.33 (6.47,13.6) | 16.3 (10.7,25.9)   | 129 (88.1,185)         | 2.00 (1.74,2.30) |
| Cohort2 (6to<12years)      | 12mg/kg q8h  |   18 | 5.09 (4.14,7.02) | 24.8 (22.1,28.8)   | 170 (127,211)          | 1.52 (1.34,1.81) |
| Cohort2 (6to<12years)      | 400mg q8h    |   15 | 7.31 (5.88,10.5) | 20.9 (14.6,28.3)   | 164 (114,204)          | 1.83 (1.59,2.03) |
| Cohort3 (2to<6years)       | 12 mg/kg q8h |   21 | 3.68 (2.50,4.52) | 24.6 (19.2,27.6)   | 175 (143,198)          | 1.55 (1.38,1.66) |
| Cohort4 (2monthsto<2years） | 12mg/kg q8h  |   21 | 2.18 (1.45,3.12) | 23.5 (19.7,29.4)   | 182 (138,248)          | 1.64 (1.37,2.08) |
| Cohort4 (2to<6months)      | 8 mg/kg q8h  |    2 | 1.25 (0.99-1.5)  | 13.7 (11.89-15.49) | 108 (100-115.15)       | 1.66 (1.44-1.89) |

<div style=\"page-break-after: always\"></div>

## Table 11 Median (90% confidence interval) ceftaroline PK parameters by cohort and dose based on individual population PK model-predicted parameters for study P90331

| Cohort (Age Range)            | Dose?        | nb   | CL, L/h           | Cmax, μg/mL      | AUC0-24h.s9 μgoh/mL   | Ty, h            |
|-------------------------------|--------------|------|-------------------|------------------|-----------------------|------------------|
| Cohort 1 (12 to<18 years)     | 400mg q8h    | 8    | 7.54 (5.49,13.4)  | 18.6 (9.88,25.7) | 159 (92.6,219)        | 2.01 (1.79,2.45) |
| Cohort 2 (6 to<12years)       | 12 mg/kg q8h | 17   | 4.61 (3.01,5.81)  | 23.4 (13.2,32.6) | 189 (132,279)         | 1.65 (1.23,1.91) |
| Cohort 2 (6 to < 12 years)    | 400mg q8h    | 6    | 6.14 (3.38,9.23)  | 22.7 (14.5,33.8) | 196 (131,358)         | 1.89 (1.76,2.52) |
| Cohort 3 (2 to <6 years)      | 12 mg/kg q8h | 60   | 3.28 (2.01,4.83)  | 24.7 (11.8,30.8) | 181 (135,252)         | 1.54 (1.28,2.03) |
| Cohort 3 (2 to <6 years)      | 400 mg q8h   | 1    | 5.26 (5.26-5.26)  | 27. (27.9-27.9)  | 228(228.14- 228.14)   | 1.96 (1.96-1.96) |
| Cohort 3 (2 to <6 years)      | 4 mg/kg q8h  |      | 3.76 (3.76-3.76)  | 6.45 (6.45-6.45) | 51.1 (51.06-51.06)    | 1.53 (1.53-1.53) |
| Cohort 4 (2 months to<2years) | 12 mg/kg q8h | 18   | 1.84 (1.22,3.03)  | 24.7 (18.6,31.8) | 205 (154,285)         | 1.73 (1.36,2.24) |
| Cohort 4 (2to<6 months)       | 8 mg/kg q8h  | 5    | 1.17 (0.662,1.44) | 17.8 (13.0,20.6) | 139 (106,192)         | 1.90 (1.44,2.01) |

## Table 12 Median (90% confidence interval) ceftaroline PK parameters by cohort and dose based on individual population PK model-predicted parameters for study P90324

| Cohort (Age Range)          | Dosea        |   nb | CL,L/h           | Cmax, g/mL       | AUC0-24h.ss9 μgh/mL                           | Tz, h            |
|-----------------------------|--------------|------|------------------|------------------|-----------------------------------------------|------------------|
| Cohort 1 (12to<18years)     | 600mg q8h    |    5 | 12.6 (6.02,14.9) | 12.7 (10.9,22.4) | 143 (121,309)                                 | 2.09 (1.81,2.46) |
| Cohort 2 (6 to<12years)     | 600mg q8h    |    1 | 8.66 (8.66-8.66) | 20.2 (20.2-20.2) | 208 (207.85- 207.85)                          | 1.61 (1.61-1.61) |
| Cohort2 (6 to < 12 years)   | 15 mg/kg q8h |    6 | 5.01 (4.56,7.34) | 18.8 (16.0,24.6) | 186 (176,256)                                 | 1.52 (1.34,1.82) |
| Cohort3 (2 to < 6 years)    | 15 mg/kg q8h |   11 | 3.60 (2.30,5.72) | 21.4 (17.2,25.3) | 224 (166,258)                                 | 1.53 (1.38,1.72) |
| Cohort 4 (2monthsto<2years) | 15 mg/kg q8h |    4 | 1.42 (1.16-2.85) | 25.9             | 287 (18.36-27.66) (173.68-331.03) (1.35-2.07) | 1.82             |
| Cohort4 (2 to<6 months)     | 10 mg/kg q8h |    2 | 1.42 (1.28-1.55) | 13.5             | 162 (13.28-13.78) (145.16-178.12) (1.73-1.77) | 1.75             |

One hundred simulations were performed for each mg/kg dose, with 600 (300 male and 300 female) patients  per  1  week  age  group  from  28  to  40  post-menstrual  weeks  for  each  renal  function  category (normal  renal  function  or  mild,  moderate,  or  severe  renal  impairment)  and  600  (300  male  and  300 female) patients from each 1 month age group from 0 to &lt;18 years for each renal function category for each simulation. For adults, 300 patients were simulated for each dose and renal function category for each of the 100 simulated data sets. Results were summarized as the median (90% prediction interval),

<div style=\"page-break-after: always\"></div>

calculated as median (of the 100 medians), median (of the 100 5th percentiles) and median (of the 100 95th percentiles) by age group.

From these simulations the area under the AUC24SS and CmaxSS  were compared to simulations for adult patients at steady-state. Paediatric simulations using 1 h infusions were compared to adults dosed with 600 mg q12h over 1 h and those using 2 h infusions were compared to adults dosed with 600 mg q8h with a 1 or 2 h infusion. Simulations are summarized by age group for normal renal function patients and those with mild impairment according to the regimens used in P903-23 and P903-31. It should be noted that  the  600  mg  q8h  adult  dose  regimen  is  not  currently  approved  in  adults  and  the  MAH  does  not propose to include equivalent dosing for children in this extension of indication application.

Table 13 Median (90% PI) ceftaroline Cmax,ss and AUC24, ss by age following doses used in studies P903-23 and P903-31 to steady-state in paediatric patients with normal renal functions, based on simulations

<!-- image -->

| AGE                     | Weight (kg)      | Cmaxss (Img/L)   | AUC24ss (mg*hr/L)   | Dose*                   |
|-------------------------|------------------|------------------|---------------------|-------------------------|
| Adults 600 mg q12h 1 hr | 77.6 (52.5,105)  | 21.0 (11.9,36.5) | 97.3 (59.1,164)     | 600mg                   |
| 12-<18years             | 52.9 (36.8,75.3) | 19.7 (11.0,34.2) | 122 (72.7,201)      | 12mg/kg(maxof400mg)     |
| 6-<12 years             | 28.5 (19.3,46.5) | 27.6 (16.4,43.3) | 157 (99.7,245)      | 12 mg/kg (max of400 mg) |
| 2-<6 years              | 15.8 (11.8,22.2) | 27.1 (16.8,41.8) | 144 (92.6,225)      | 12mg/kg(maxof400mg)     |
| 18-<24months            | 11.7 (9.81,14.1) | 28.3 (17.6,43.4) | 160 (104,247)       | 12mg/kg(maxof400mg)     |
| 12-<18months            | 10.4 (8.60,12.7) | 28.7 (17.9,44.0) | 168 (109,260)       | 12mg/kg(maxof400mg)     |
| 6-<12months             | 8.43 (6.55,10.7) | 29.3 (18.2,45.1) | 182 (116,282)       | 12mg/kg(maxof400mg)     |
| 2-<6months              | 5.75 (4.12,7.66) | 19.2 (12.1,29.7) | 134 (86.6,208)      | 8 mg/kg(max of400 mg)   |

Median(5th,95th percentile)basedonsummaryof100trials andcorrespondstomedian(90%P1).Adult dose andregimenislistedinfirstrowofcolumn1.*Paediatricdoseadministeredq8has1hourinfusion

Table 14 Median (90% PI) ceftaroline Cmax,ss and AUC24, ss by age following doses used in studies P903-23 and P903-31 to steady-state in paediatric patients with mild renal impairment, based on simulations

<!-- image -->

| AGE                     | Weight (kg)       | Cmaxss (Img/L)   | AUC24ss (mg*hr/L)   | Dose*                   |
|-------------------------|-------------------|------------------|---------------------|-------------------------|
| Adults 600 mg q12h 1 hr | 75.4 (51.9, 99.9) | 22.5 (12.8,39.2) | 113 (66.7,197)      | 600mg                   |
| 12-<18 years            | 52.7 (36.7,74.7)  | 20.7 (11.5,35.6) | 136 (80.9,227)      | 12mg/kg(maxof400mg)     |
| 6-<12 years             | 28.6 (19.2,46.8)  | 28.8 (17.0,45.4) | 175 (110,276)       | 12mg/kg(maxof400mg)     |
| 2-<6 years              | 15.8 (11.8,22.4)  | 28.3 (17.5,44.0) | 160 (102,252)       | 12mg/kg(maxof400mg)     |
| 18-<24months            | 11.7 (9.82,14.1)  | 31.0 (19.1,47.9) | 201 (124,325)       | 12mg/kg(maxof400mg)     |
| 12-<18months            | 10.4 (8.58,12.7)  | 31.5 (19.5,48.9) | 210 (130,343)       | 12 mg/kg (max of400 mg) |
| 6-<12months             | 8.43 (6.56,10.8)  | 32.2 (20.0,49.9) | 227 (140,370)       | 12mg/kg(maxof400mg)     |
| 2-<6months              | 5.75 (4.11,7.67)  | 21.2 (13.2,33.3) | 168 (103,275)       | 8mg/kg(maxof400 mg)     |

Median(5th,95 percentile)basedonsummaryof100trials andcorrespondstomedian(90%PI).Adultdose andregimenislistedinfirstrowofcolumn1.*Paediatricdoseadministeredq8has1hourinfusion.

The median Cmax and AUC values in children aged 2 months to &lt;18 years with normal renal function dosed with the regimens used in studies P903-23 and P903-31 were predicted to be up to 40% and 87% greater,  respectively,  than  the  median  Cmax  and  AUC  values  in  adults  dosed  with  600  mg q12h.  The median Cmax and AUC values in children aged 2 months to &lt;18 years with mild renal impairment dosed with the above regimen were predicted to be up to 43% and 100% greater, respectively, than the median Cmax and AUC values in adults dosed with 600 mg q12h.

Although  no  new  safety  issues  were  identified  with  the  dose  regimens  used  in  P903-23,  P903-31  and P903-24  the  increased  exposure  in  paediatric  patients  relative  to  the  median  exposure  in  adults

<div style=\"page-break-after: always\"></div>

suggested that doses that are lower and more reflective of exposure in adults may be efficacious in the ≤24 months age group.

## Proposed paediatric doses

The  % f T&gt;MIC for  ceftaroline  was  previously  identified  as  the  PK/PD  index  and  the  PK/PD  targets  are shown below for Staphylococcus aureus , Streptococcus pneumoniae and Enterobacteriaceae based on a neutropenic murine thigh and lung infection model.

Table 15 Median (min-max range) of the PK/PD target (%fT&gt;MIC) based on in vivo efficacy of ceftaroline in the neutropenic murine thigh infection model against various CAP pathogens

|                                 | Median%fT>MIC (range)   | Median%fT>MIC (range)   | Median%fT>MIC (range)   |
|---------------------------------|-------------------------|-------------------------|-------------------------|
| Organism ()                     | Stasis                  | 1 logio kill            | 2 log1o kill            |
| Staphylococcusaureus(n=4)       | 26% (15-36%)            | 35% (18-44%)            | 51% (23-56%)            |
| Streptococcuspneumoniae(n=5)    | 35% (29-52%)            | 44% (33-59%)            | 51% (36-64%)            |
| Enterobacteriaceae(E.coli[n=2], | 48.5% (30-59%)          | 73%(39-89%)             | ND                      |
| K. pneumoniae[n=2])*            |                         |                         |                         |

Source:ReportP0903-M-003Addendum1.

串 K.pneumoniae 43816(lung) data are includedforstasis and1logiokillbut 2-1ogiokill data are only availableforthestrainsE.coli25922vieldingavalueof47%T&gt;MIC.

Paediatric dose selection was based on predictions of achieving 36%, 44% or 73% f T&gt;MIC for S. aureus, S.  pneumoniae and Enterobacteriaceae ,  respectively.  The  final  dose  selection  was  based  on  achieving &gt;90% PTA against the current breakpoints of 1 mg/L for S. aureus , 0.25 mg/L for S. pneumoniae and 0.5 mg/L for Enterobacteriaceae .

Based on meeting the criteria  described  above the  proposed  doses  for  paediatric  patients  are  not  the same  as  the  doses  used  in  the  clinical  studies.  As  shown  below,  12  mg/kg  q8h  as  a  1  h  infusion  in children aged from ≥ 24 months to &lt; 18 years and 8 mg/kg q8h as 1 h infusion in children aged from ≥ 2 months to &lt; 24 months achieved good PTA in subsets with normal and mildly impaired renal function:

Table 16 Probability of target attainment by MIC and age group based on simulations for paediatric patients with normal renal function following proposed paediatric doses

| MIC         | Age Range, Dosea           | Age Range, Dosea         | Age Range, Dosea        | Age Range, Dosea         | Age Range, Dosea         | Age Range, Dosea      | Age Range, Dosea       | Age Range, Dosea   |
|-------------|----------------------------|--------------------------|-------------------------|--------------------------|--------------------------|-----------------------|------------------------|--------------------|
| (mg/L)      | 12 to<18years 12 mg/kg qSh | 6to<12years 12 mg/kg q8h | 2to<6years 12 mg/kg qSh | 18to<24months 8mg/kg qSh | 12to<18months 8mg/kg q8h | 6to<12months 8mg/kqSh | 2to<6months 8mg/kg q8h | Adults, 600mg q12h |
|             | 36% fT>MIIC                | 36% fT>MIIC              | 36% fT>MIIC             | 36% fT>MIIC              | 36% fT>MIIC              | 36% fT>MIIC           | 36% fT>MIIC            | 36% fT>MIIC        |
| 0.125       | 100                        | 100                      | 100                     | 100                      | 100                      | 100                   | 100                    | 100                |
| 0.25        | 100                        | 100                      | 100                     | 100                      | 100                      | 100                   | 100                    | 100                |
| 0.5         | 100                        | 100                      | 100                     | 100                      | 100                      | 100                   | 100                    | 100                |
| 1           | 100                        | 100                      | 100                     | 100                      | 100                      | 100                   | 100                    | 99.7               |
| 2           | 97.0                       | 99.4                     | 98.2                    | 94.0                     | 95.9                     | 98.5                  | 99.8                   | 81.0               |
| 4           | 44.7                       | 71.6                     | 56.8                    | 28.3                     | 36.0                     | 48.4                  | 68.5                   | 16.3               |
| 8           | 1.33                       | 5.00                     | 2.25                    | 0.167                    | 0.250                    | 0.833                 | 2.75                   | 0.333              |
| 44% fT>MIIC | 44% fT>MIIC                | 44% fT>MIIC              | 44% fT>MIIC             | 44% fT>MIIC              | 44% fT>MIIC              | 44% fT>MIIC           | 44% fT>MIIC            | 44% fT>MIIC        |
| 0.125       | 100                        | 100                      | 100                     | 100                      | 100                      | 100                   | 100                    | 100                |
| 0.25        | 100                        | 100                      | 100                     | 100                      | 100                      | 100                   | 100                    | 100                |
| 0.5         | 100                        | 100                      | 100                     | 100                      | 100                      | 100                   | 100                    | 100                |
| 1           | 99.8                       | 100                      | 99.8                    | 99.3                     | 99.7                     | 99.8                  | 100                    | 95.5               |
| 2           | 88.2                       | 95.5                     | 89.1                    | 76.8                     | 82.2                     | 90.7                  | 97.5                   | 53.2               |
| 4           | 22.7                       | 42.5                     | 27.8                    | 10.3                     | 14.0                     | 23.2                  | 43.5                   | 5.00               |
| 8           | 0.333                      | 1.17                     | 0.50                    | 0.00                     | 0.00                     | 0.167                 | 0.75                   | 0.00               |

<div style=\"page-break-after: always\"></div>

|   73%fT>MIIC |   73%fT>MIIC |   73%fT>MIIC |   73%fT>MIIC |   73%fT>MIIC |   73%fT>MIIC |   73%fT>MIIC |   73%fT>MIIC |   73%fT>MIIC |
|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
|        0.125 |      100     |        100   |        100   |       100    |       100    |      100     |       100    |        99.7  |
|        0.25  |      100     |        100   |         99   |        98.8  |        99.3  |       99.7   |       100    |        95.7  |
|        0.5   |       97.7   |         97.5 |         90.4 |        87.4  |        91.2  |       95.7   |        99    |        73    |
|        1     |       73.7   |         77.3 |         55.8 |        46.2  |        54.3  |       68.1   |        87.6  |        29    |
|        2     |       18.8   |         25.8 |         11.8 |         5.83 |         8.83 |       15.6   |        37    |         3.33 |
|        4     |        0.667 |          1.5 |          0.5 |         0    |         0    |        0.333 |         2.25 |         0    |
|        8     |        0     |          0   |          0   |         0    |         0    |        0     |         0    |         0    |

Table 17 Probability of target attainment by MIC and age group based on simulations for paediatric patients with mild renal impairment following proposed paediatric doses

| MIC         | Age Range, Dosea           | Age Range, Dosea            | Age Range, Dosea           | Age Range, Dosea          | Age Range, Dosea          | Age Range, Dosea      | Age Range, Dosea         | Age Range, Dosea   |
|-------------|----------------------------|-----------------------------|----------------------------|---------------------------|---------------------------|-----------------------|--------------------------|--------------------|
| (mg/L)      | 12 to<18years 12 mg/kg qSh | 6 to <12 years 12 mg/kg qSh | 2 to <6 years 12 mg/kg qSh | 18to<24months 8 mg/kg qSh | 12to<18months 8 mg/kg q8h | 6to<12months 8mg/kqSh | 2 to<6months 8 mg/kg qSh | Adults, 600mgq12h  |
|             | 36% fT>MIC                 | 36% fT>MIC                  | 36% fT>MIC                 | 36% fT>MIC                | 36% fT>MIC                | 36% fT>MIC            | 36% fT>MIC               | 36% fT>MIC         |
| 0.125       | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 100                |
| 0.25        | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 100                |
| 0.5         | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 100                |
| 1           | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 99.7               |
| 2           | 8'86                       | 99.8                        | 99.2                       | 98.8                      | 99.3                      | 8'66                  | 100                      | 81.0               |
| 4           | 60.0                       | 858                         | 72.6                       | 61.8                      | 68.5                      | 78.4                  | 89.5                     | 16.7               |
| 8           | 3.50                       | 11.6                        | 6.25                       | 3.50                      | 5.00                      | 9.17                  | 16.8                     | 0.00               |
| 44% fI>MIIC | 44% fI>MIIC                | 44% fI>MIIC                 | 44% fI>MIIC                | 44% fI>MIIC               | 44% fI>MIIC               | 44% fI>MIIC           | 44% fI>MIIC              | 44% fI>MIIC        |
| 0.125       | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 100                |
| 0.25        | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 100                |
| 0.5         | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 100                |
| 1           | 100                        | 100                         | 100                        | 99.8                      | 100                       | 100                   | 100                      | 95.7               |
| 2           | 94.0                       | 98.2                        | 95.1                       | 99.3                      | 95.6                      | 97.9                  | 99.5                     | 52.8               |
| 4           | 38.0                       | 61.2                        | 44.2                       | 39.7                      | 45.8                      | 58.9                  | 75.1                     | 5.33               |
| 8           | 1.17                       | 3.83                        | 1.75                       | 1.17                      | 1.83                      | 3.50                  | 8.50                     | 0.00               |
| 73% fT>MIIC | 73% fT>MIIC                | 73% fT>MIIC                 | 73% fT>MIIC                | 73% fT>MIIC               | 73% fT>MIIC               | 73% fT>MIIC           | 73% fT>MIIC              | 73% fT>MIIC        |
| 0.125       | 100                        | 100                         | 100                        | 100                       | 100                       | 100                   | 100                      | 99.7               |
| 0.25        | 100                        | 100                         | 99.5                       | 99.8                      | 99.8                      | 100                   | 100                      | 95.8               |
| 0.5         | 99.2                       | 99.0                        | 95.5                       | 97.0                      | 98.2                      | 99.2                  | 99.8                     | 72.7               |
| 1           | 85.8                       | 88.2                        | 71.9                       | 78.8                      | 83.7                      | 90.4                  | 97.0                     | 27.7               |
| 2           | 34.8                       | 43.4                        | 25.0                       | 32.5                      | 39.5                      | 52.7                  | 72.9                     | 3.00               |
| 4           | 2.33                       | 4.67                        | 1.75                       | 2.75                      | 4.25                      | 7.83                  | 18.2                     | 0.00               |
| 8           | 0.00                       | 0.00                        | 0.00                       | 0.00                      | 0.00                      | 0.00                  | 0.250                    | 0.00               |

Based on the PTA the proposed q8h dose for those aged 6 to &lt;24 months has been lowered from that used in the clinical studies (see predicted exposures at the doses that were used in tables 5 and 6 above, which include the 2-&lt;6 month group not shown again in Table 10) to 8 mg/kg q8h. This dose reduces the exposures in children aged 6-24 months and makes them more comparable with adults as shown below.

<div style=\"page-break-after: always\"></div>

Table 18 Median (90% PI) ceftaroline steady-state Cmax, ss and AUC24,ss, by age following the proposed dose for subjects aged from 6 to &lt;24 months in paediatric patients with either normal renal function, or mild renal impairment based on simulations

<!-- image -->

| AGE                                        | Weight (kg)                                | Cmaxss (mg/L)                              | AUC24ss(mg*hr/L)                           | Dose*                                      |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Adults600mg q12h 1 hr                      | 77.6 (52.5,105)                            | 21.0 (11.9,36.5)                           | 97.3 (59.1,164)                            | 600mg                                      |
| Normalrenalfunction（CrCL>80ml/min)         | Normalrenalfunction（CrCL>80ml/min)         | Normalrenalfunction（CrCL>80ml/min)         | Normalrenalfunction（CrCL>80ml/min)         | Normalrenalfunction（CrCL>80ml/min)         |
| 12-<18years                                | 52.9 (36.8,75.3)                           | 19.7 (11.0,34.2)                           | 122 (72.7,201)                             | 12mg/kg(maxof400mg)                        |
| 6-<12years                                 | 28.5 (19.3,46.5)                           | 27.6 (16.4,43.3)                           | 157 (99.7,245)                             | 12mg/kg(maxof400mg)                        |
| 2-<6 years                                 | 15.8 (11.8,22.2)                           | 27.1 (16.8,41.8)                           | 144 (92.6,225)                             | 12mg/kg(maxof400mg)                        |
| 18-<24months                               | 11.7 (9.8,14.1)                            | 18.8 (11.8,29.1)                           | 107 (69.0,165)                             | 8mg/kg（maxof400 mg)                        |
| 12-<18months                               | 10.4 (8.6,12.7)                            | 19.1 (11.9,29.4)                           | 113 (71.8,174)                             | 8mg/kg（maxof400 mg)                        |
| 6-<12months                                | 8.43(6.55,10.7)                            | 19.6 (12.2,30.0)                           | 120 (78.3,188)                             | 8 mg/kg (max of 400 mg)                    |
| Mildrenalimpairment(>50ml/minCrCL<80ml/min | Mildrenalimpairment(>50ml/minCrCL<80ml/min | Mildrenalimpairment(>50ml/minCrCL<80ml/min | Mildrenalimpairment(>50ml/minCrCL<80ml/min | Mildrenalimpairment(>50ml/minCrCL<80ml/min |
| Adults 600mg q12h1 hr                      | 77.6(52.2,105)                             | 20.9 (11.7,36.6)                           | 97.1 (58.8,164)                            | 600mg                                      |
| 12-<18years                                | 52.7 (36.7,74.7)                           | 20.7 (11.5,35.6)                           | 136 (80.9,227)                             | 12mg/kg（maxof400mg)                        |
| 6-<12 years                                | 28.6 (19.2,46.8)                           | 28.8 (17.0,45.4)                           | 175 (110,276)                              | 12 mg/kg (max of 400 mg)                   |
| 2-<6years                                  | 15.8(11.8,22.4)                            | 28.3 (17.5,44.0)                           | 160 (102,252)                              | 12mg/kg(maxof400mg)                        |
| 18-<24months                               | 11.7 (9.8,14.1)                            | 20.6 (12.8,32.3)                           | 133 (82.7,219)                             | 8mg/kg（maxof400mg)                         |
| 12-<18months                               | 10.4 (8.6,12.7)                            | 20.9 (13.0,32.6)                           | 140 (86.0,227)                             | 8mg/kg(maxof400 mg)                        |
| 6-<12months                                | 8.43 (6.55,10.7)                           | 21.4 (13.3,33.3)                           | 152 (92.6,247)                             | 8 mg/kg (max of400 mg)                     |

## Additional analyses reported in CPT-MS-08

## Infants &lt; 2 months

CHMP  noted  that  the  MAH  did  not  explain  why  dose  recommendations  are  not  made  for  infants  &lt;  2 months and that it did not discuss the additional analyses provided in CPT-MS-08.

The  following  tables  present  the  target  data  as  median  (90%  prediction  interval)  of  the  %fT&gt;MIC predicted.

A dose of 4 mg/kg q8h as a 1 h infusion to preterm neonates (GA 28 to &lt; 40 weeks) and infants up to &lt; 2 months is predicted to provide median ceftaroline AUC24SS that range from 59.5% to 77.8% and median ceftaroline  CmaxSS that  range  from  35.3%  to  44.7%  of  the  respective  adult  median  values  using  the approved adult dose. The report states that the median free percent time above MIC ( f PTAM) for MICs of 1 and 2 mg/L were similar to or exceeded median f PTAM values in adults.

<div style=\"page-break-after: always\"></div>

Table 19 Median (90% PI) ceftaroline state Cmax, ss AUC24,ss %T&gt;MIC by age for normal renal function following doses used in studies P903-23 and P903-31 to steadystate for ceftaroline in paediatric patients based on simulations

<!-- image -->

Corresponding predicted AUC and Cmax values (for 4 mg/kg q8h as a 1 h infusion to preterm neonates GA 28 to &lt; 40 weeks and infants up to &lt; 2 months) in the presence of mild renal impairment are higher (74.6%  to  97.6%  and  38.9%  to  49.2%,  respectively)  than  shown  above.  The  report  states  that  the median f PTAM for MICs of 1 and 2 mg/L exceeded median f PTAM values in adults.

Table 20 Median (90% PI) ceftaroline state Cmax, ss AUC24,ss %T&gt;MIC by age for mild renal impairment following doses used in studies P903-23 and P903-31 to steadystate for ceftaroline in paediatric patients based on simulations

<!-- image -->

Additional tables  were  generated to  compare  PK  in  children  dosed  q8h  using  2-h  infusions  with  adults dosed  q8h  dosing  using  1-h  or  2-h  infusions.  The  predicted  exposures  at  these  alternative  paediatric doses using 2 h infusions are of some interest and can be compared to the results in adults using the approved regimen of q12h with 1 h infusions as shown in the tables above.

Compared to the approved adult dose in normal renal function (600 mg q12h using 1-h infusions) shown in the tables above, 5 mg/kg doses using 2-h infusions in the age groups shown in the tables below give similar or slightly lower AUCs.

<div style=\"page-break-after: always\"></div>

Table 21 Median (90% PI) ceftaroline Cmax, ss AUC24,ss %T&gt;MIC by age for normal renal function following doses used in studies P903-24 to steady-state for ceftaroline in paediatric patients based on simulations

<!-- image -->

| AGE               | Weight (kg)       | CmaxSS (mg/L)    | AUC24SS(mg*hr/L)   | %T>MICof1 mg/L   | %T>MICof2mg/L    | Dose*               |
|-------------------|-------------------|------------------|--------------------|------------------|------------------|---------------------|
| Adults600mgq8h1hr | 77.6 (52.5,105)   | 21.8(12.5,38.0)  | 146 (87.8,249)     | 96.3 (67.9,100)  | 70.4 (45.7,98.8) | 600mg               |
| Adults600mgq8h2hr | 77.6 (52.5,105)   | 17.6(10.5,29.3)  | 146(88.6,246)      | 98.8(75.3,100)   | 76.5(51.8,100)   | 600mg               |
| 12-<18years       | 52.9 (36.8,75.3)  | 23.2(13.7,37.3)  | 182(110,293)       | 98.8 (77.8,100)  | 80.2(56.8,100)   | 15mg/kg（maxof600mg) |
| 6-<12years        | 28.5 (19.3,46.5)  | 27.5 (17.5,41.4) | 205(131,316)       | 97.5 (74.1,100)  | 78.7(56.8,100)   | 15mg/kg（maxof600mg) |
| 2-<6years         | 15.8 (11.8,22.2)  | 25.5(16.6,38.2)  | 180(116,279)       | 88.9 (66.6,100)  | 69.1 (50.6,95.1) | 15mg/kg（maxof600mg） |
| 18-<24months      | 11.7 (9.81,14.1)  | 27.1 (17.5,40.6) | 200(130,310)       | 95.7 (72.8,100)  | 76.5 (56.8,98.8) | 15mg/kg（maxof600mg) |
| 12-<18months      | 10.4 (8.60,12.7)  | 27.7(18.0,41.6)  | 210(135,324)       | 97.5 (75.3,100)  | 79.0(59.2,100)   | 15mg/kg（maxof600mg) |
| 6-<12months       | 8.43 (6.55,10.7)  | 28.9 (18.7,43.2) | 227 (147,350)      | 100 (80.2,100)   | 85.2(63.0,100)   | 15mg/kg（maxof600mg) |
| 2-<6months        | 5.75 (4.12,7.66)  | 19.8(12.8,29.7)  | 168(109,260)       | 98.8 (79.0,100)  | 82.7(59.3,100)   | 10mg/kg（maxof600mg) |
| 1.<2months        | 4.69 (3.63,5.77)  | 9.74 (6.24,14.7) | 87.3(56.5,134)     | 88.3 (63.0,100)  | 59.3 (38.2,86.5) | 5mg/kg（maxof600mg)  |
| 0-<1month         | 3.88 (2.91,4.75)  | 9.50 (6.15,14.5) | 90.0(58.6,138)     | 93.8 (67.9,100)  | 63.0 (40.7,91.4) | 5mg/kg（maxof600mg）  |
| GA38-<40weeks     | 3.40 (2.55,4.24)  | 9.29 (5.93,14.2) | 94.9 (61.9,147)    | 98.8 (75.3,100)  | 70.4 (44.4,97.5) | 5mg/kg（maxof600mg）  |
| GA36-<38weeks     | 2.87 (2.07,3.75)  | 9.06 (5.81,13.9) | 91.1(59.3,141)     | 97.5 (72.8,100)  | 66.7 (41.9,95.1) | 5mg/kg（maxof600mg)  |
| GA34-<36weeks     | 2.32(1.71,3.05)   | 8.76 (5.62,13.5) | 86.8 (56.2,134)    | 95.1 (69.1,100)  | 63.0 (38.3,92.6) | 5mg/kg（maxof600 mg) |
| GA32-<34weeks     | 1.89 (1.38,2.44)  | 8.55(5.45,13.1)  | 82.3 (53.6,127)    | 91.4 (65.4,100)  | 59.3 (35.8,87.7) | 5mg/kg（maxof600mg)  |
| GA30-32weeks      | 1.50 (1.05,1.95)  | 8.17 (5.21,12.6) | 77.5 (50.1,120)    | 87.7 (61.7,100)  | 55.2(33.3,84.0)  | 5mg/kg（maxof600mg)  |
| GA28-<30weeks     | 1.15 (0.779,1.52) | 7.85(4.99,12.2)  | 72.4 (46.4,113)    | 81.5(58.0,100)   | 50.6(29.6,77.8)  | 5mg/kg（maxof600mg)  |

Table 22 Median (90% PI) ceftaroline Cmax, ss AUC24,ss %T&gt;MIC by age for mild renal impairment following doses used in studies P903-24 to steady-state for ceftaroline in paediatric patients based on simulations

<!-- image -->

| AGE               | Weight(kg)        | CmaxSS (mg/L)    | AUC24SS(mg*hr/L)   | %T>MICof1mg/L   | %T>MICof2mg/L    | Dose\"                  |
|-------------------|-------------------|------------------|--------------------|-----------------|------------------|------------------------|
| Adults600mgq8h1hr | 77.6 (52.2,105)   | 21.9 (12.4,38.3) | 146 (87.8,249)     | 96.3 (67.9,100) | 70.4 (45.7,98.8) | 600mg**                |
| Adults600mgq8h2hr | 77.6 (52.2,105)   | 17.5 (10.5,29.4) | 146(87.9,248)      | 98.8 (75.2,100) | 76.5 (51.8,100)  | 600mg**                |
| Adults600mgq8h1hr | 75.4 (51.9,99.9)  | 23.6(13.5,41.3)  | 170 (100,296)      | 100 (76.4,100)  | 82.7(51.9,100)   | 600mg***               |
| Adults600mgq8h2hr | 75.4 (51.9,99.9)  | 19.4(11.5,32.7)  | 169 (101,295)      | 100 (82.7,100)  | 88.6 (58.0,100)  | 600mg***               |
| 12-<18years       | 52.7 (36.7,74.7)  | 24.5(14.5,40.0)  | 202(121,329)       | 100 (84.0,100)  | 88.9 (61.7,100)  | 15mg/kg（maxof600mg)    |
| 6-<12years        | 28.6 (19.2,46.8)  | 29.2(18.5,44.3)  | 227 (144,358)      | 100(80.2,100)   | 86.4(61.7,100)   | 15mg/kg（maxof600mg)    |
| 2-<6years         | 15.8 (11.8,22.4)  | 27.1 (17.5,40.8) | 199 (127,313)      | 95.1(70.4,100)  | 75.3 (55.5,98.8) | 15mg/kg(maxof600 mg)   |
| 18-<24months      | 11.7 (9.82,14.1)  | 30.8 (19.6,47.1) | 251 (154,409)      | 100 (82.7,100)  | 92.6 (65.4,100)  | 15mg/kg(max of 600 mg) |
| 12-<18months      | 10.4 (8.58,12.7)  | 31.3 (20.0,48.1) | 262(163,428)       | 100 (85.2,100)  | 95.1 (67.9,100)  | 15mg/kg（maxof600mg)    |
| 6-<12months       | 8.43 (6.56,10.8)  | 32.8 (21.0,49.8) | 284 (176,459)      | 100 (92.5,100)  | 98.8 (72.8,100)  | 15mg/kg（maxof 600 mg)  |
| 2-<6months        | 5.75 (4.11,7.67)  | 22.3 (14.2.34.3) | 210(130,343)       | 100(91.3,100)   | 97.5 (69.1,100)  | 10mg/kg（maxof600 mg)   |
| 1-<2months        | 4.69 (3.63,5.77)  | 11.1 (6.99,17.1) | 109 (67.6,177)     | 98.8 (74.1,100) | 75.3(46.9,100)   | 5mg/kg（maxof600mg)     |
| 0-<lmonth         | 3.86 (2.91,4.75)  | 10.8 (6.88,16.7) | 113 (69.7,181)     | 100 (80.2,100)  | 81.5 (49.4,100)  | 5mg/kg（maxof600mg)     |
| GA38-<40weeks     | 3.40 (2.56,4.26)  | 10.7 (6.74,16.6) | 119 (74.1,193)     | 100 (90.1,100)  | 90.1(55.5,100)   | 5mg/kg（maxof600mg)     |
| GA36-<38weeks     | 2.86(2.06,3.77)   | 10.3 (6.55,16.3) | 114 (70.1,186)     | 100 (85.2,100)  | 86.4 (51.8,100)  | 5mg/kg（maxof600mg)     |
| GA34-<36weeks     | 2.33 (1.73,3.06)  | 10.0 (6.32,15.8) | 109 (66.8,176)     | 100 (81.5,100)  | 82.7(48.1,100)   | 5mg/kg（maxof600mg)     |
| GA32-<34weeks     | 1.89 (1.38,2.44)  | 9.73 (6.12,15.1) | 103 (63.4,166)     | 100 (77.8,100)  | 77.8(45.6,100)   | 5mg/kg（maxof600mg)     |
| GA30-<32weeks     | 1.50 (1.06,1.95)  | 9.32(5.85,14.5)  | 97.0 (59.7,158)    | 98.8 (72.8,100) | 71.6 (41.9,98.8) | 5mg/kg（maxof600mg)     |
| GA 28-<30weeks    | 1.16 (0.779,1.53) | 8.98 (5.60,14.1) | 90.4 (55.6,148)    | 96.3 (67.9,100) | 66.7 (38.3,97.5) | 5mg/kg（maxof600mg)     |

*Paediatric dose administered q8h as 2 hour infusion. **Results for adults with normal renal function.

***Results for adults with mild renal impairment.

It  was  clarified  by  the  MAH  during  the  procedure  that  dosing  recommendations  for  children  below  2 months of age will be the subject of a future application and that the suitability of the dose resulting from the above (5 mg/kg in a 2h infusion) will be considered, along with the suitability of any other proposed dose. This was agreed by CHMP.

## Adolescents 12 - &lt; 17 years

The initial dose recommendation proposed by the MAH for adolescents (400 mg q8h) differed from that in adults (600 mg q12h). Since it was unusual that adolescents are dosed differently to adults with antibacterial agents, especially for beta-lactam agents with relatively simple pharmacokinetics, CHMP asked the MAH to clarify this aspect.

<div style=\"page-break-after: always\"></div>

The  updated  report  presented  results  from  Monte  Carlo  simulations  that  used  the  final  population  PK model,  a  measure  of  parameter  uncertainty  and  appropriate  covariate  distributions  for  steady-state simulations  of  ceftaroline.    Simulations  were  performed  for  the  approved  adult  regimen  and  dosing regimens  for  patients  aged  6  to  &lt;18  years  with  normal  renal  function  or  mild  or  moderate  renal impairment. Covariates for the adult simulations were generated from a multivariate normal distribution based on the co-variances observed in the population PK data in patients. Weights for the paediatric age groups were based on CDC Growth Charts.

Simulations were performed for the following regimens:

- 600 mg every 12 hours as a 1 hour infusion (adult) - normal renal function
- 18 mg/kg (max 600 mg) every 12 hours as a 1 hour infusion - normal renal function
- 18 mg/kg (max 600 mg) every 12 hours as a 1 hour infusion - mild renal impairment
- 9  mg/kg  (max  400  mg  from  44.5  kg)  every  12  hours  as  a  1  hour  infusion  -  moderate  renal impairment
- 12  mg/kg  (max  400  mg  from  33  kg)  every  12  hours  as  a  1  hour  infusion  -  moderate  renal impairment

[of note, for adults with moderate renal impairment the recommended dose is 400 mg q12h]

The f PTAM and percentages of patients with a f PTAM 26%, 30%, 35%, 40%, 44%, 48.5%, 51%, 55%, 60% and 73% were presented in tabular format for MICs of 0.125 - 8 mg/L. Paediatric simulations of AUC24SS,  CmaxSS  and f PTAM  for  various  targets  were  compared  to  simulations  for  adult  patients  at steady state after administration of the approved dose. One hundred simulations were performed for each mg/kg dose, with 600 (300 male and 300 female) patients from each 1 month age group from 6-&lt; 18 years for normal renal function and mild or moderate renal impairment.

For  adults,  300  patients  were  simulated  for  each  dose  for  each  of  the  100  simulated  data  sets.  Results  were summarised as the median (90% prediction interval), calculated as median (of the 100 medians), median (of the 100 5 th percentiles and 95 th percentiles) by age group (6 to &lt; 12 and 12 to &lt; 18 years) and renal function category.

## Normal Renal Function - 1 hr infusion - 18 mg/kg q12h

The 18 mg/kg dose (max 600 mg; which would be the dose used from 33 kg upwards) given every 12 h gave estimated PK parameters in adolescents that were very similar to those using the approved dose in adults as shown below.

Table 23 Median(90%PI), ceftaroline Cmax, ss, AUC24, ss, %T&gt;MIC by age for normal renal function following 18 mg/kg (max of 600 mg) q12h dosing (1 hour infusion) to steady-state for ceftaroline in paediatric patients based on simulations

<!-- image -->

| AGE                | Weight (kg)        | Weight (kg)      | CmaxSS (mg/L)              | AUC24SS(mg'hr/L)   | %T>MICof1mg/L       | %T>MICof2mg/L       |
|--------------------|--------------------|------------------|----------------------------|--------------------|---------------------|---------------------|
| Adults600mgq12h1hr | Adults600mgq12h1hr | 77.6 (52.5,105)  | 20.9 (11.9,36.8)           | 97.7(58.9,165)     | 64.5 (44.6,93.4)    | 45.5 (29.8,68.7)    |
| 12-<18years        | 12-<18years        | 52.8 (36.9,75.1) | 28.6 (16.0,49.5)           | 122 (73.7,202)     | 64.5 (46.3,90.5)    | 47.9 (33.1,68.6)    |
| 6-<12years         | 6-<12years         | 28.5(19.3,46.6)  | 40.5 (23.7,64.0)           | 158(99.8,246)      | 64.7(47.1,89.3)     | 50.4 (36.4,70.3)    |
| AGE                | Weight (kg)        |                  | CmaxSSRatios AUC24SSRatios |                    | %T>MICoflmg/LRatios | %T>MICof2mg/LRatios |
| 12-<18years        | 52.8 (36.9,75.1)   | 1.37             | 1.25                       | 1.00               |                     | 1.05                |
| 6-<12years         | 28.5 (19.3,46.6)   | 1.94             | 1.62                       | 1.00               |                     | 1.11                |

Ratios based on summary of 100 trials. Ratios are relative to adult dosing regimen and represent ratio of paediatric median to adult median for adult dose of 600 mg q12h 1 hr inf.

<div style=\"page-break-after: always\"></div>

## Mild Renal Impairment - 1 hr infusion

The  18  mg/kg  q12h  dose  in  adolescents  with  mild  renal  impairment  gave  slightly  higher  exposures compared to adolescents with normal renal function. The ratios for Cmax and AUC vs. adults were both 1.4-fold.

Table 24 Median(90%PI),  ceftaroline  Cmax,  ss,  AUC24,  ss,  %T&gt;MIC  by  age  for  mild  renal impairment following 18 mg/kg (max of 600 mg) q12h dosing (1 hour infusion) to steady-state for ceftaroline in paediatric patients based on simulations

<!-- image -->

| AGE                    | Weight (kg)      | CmaxSS (mg/L)    | AUC24SS (mg'hr/L)   | %T>MICof1mg/L       | %T>MICof2mg/L       |
|------------------------|------------------|------------------|---------------------|---------------------|---------------------|
| Adults600mgq12h1hr     | 77.6 (52.5,105)  | 20.9 (11.9,36.8) | 97.7(58.9,165)      | 64.5 (44.6,93.4)    | 45.5 (29.8,68.7)    |
| 12-<18years 6-<12years | 52.8 (36.9,75.1) | 29.7 (16.6,51.6) | 135 (81.4,226)      | 71.3 (50.8,97.5)    | 53.5 (36.4,77.7)    |
|                        | 28.5(19.3,46.6)  | 42.1 (24.7,66.7) | 175 (110,278)       | 71.1 (51.2,97.5)    | 55.4 (39.7,79.3)    |
| AGE                    | Weight (kg)      | CmaxSSRatios     | AUC24SSRatios       | %T>MICof1mg/LRatios | %T>MICof2mg/LRatios |
| 12-<18years            | 52.8 (36.9,75.1) | 1.42             | 1.39                | 1.11                | 1.18                |
| 6-<12years             | 28.5(19.3,46.6)  | 2.02             | 1.80                | 1.10                | 1.22                |

Ratios based on summary of 100 trials. Ratios are relative to adult dosing regimen and represent ratio of paediatric median to adult median for adult dose of 600 mg q12h 1 hr inf.

Moderate Renal Impairment - 1 hr infusion

The  reduction  to  9  mg/kg  (maximum  400  mg)  q12h  gave  predicted  exposures  in  adolescents  with moderate renal impairment that were almost identical to those in adults using the approved regimen for normal renal function.

Table 25 Median(90%PI),  ceftaroline  Cmax,  ss,  AUC24,  ss,  %T&gt;MIC  by  age  for  moderate renal  impairment  following  9  mg/kg  (max  of  400  mg)  q12h  dosing  (1  hour infusion) to steady-state for ceftaroline in paediatric patients based on simulations

<!-- image -->

| AGE                | AGE                | Weight (kg)      | CmaxSS (mg/L)    | AUC24SS(mghr/L)     | %T>MICof1mg/L       | %T>MICof2mg/L       |
|--------------------|--------------------|------------------|------------------|---------------------|---------------------|---------------------|
| Adults600mgql2h1hr | Adults600mgql2h1hr | 77.6 (52.5,105)  | 20.9 (11.9,36.8) | 97.7 (58.9,165)     | 64.5 (44.6,93.4)    | 45.5 (29.8,68.7)    |
| 12-<18years        | 12-<18years        | 52.8 (36.9,75.1) | 20.9 (11.9,34.9) | 111 (67.9,180)      | 76.0 (52.9,99.2)    | 53.7(35.5,81.0)     |
| 6-<12years         | 6-<12years         | 28.5(19.3,46.6)  | 23.9 (14.4,37.4) | 115 (73.2,183)      | 70.2(49.6,98.3)     | 52.1 (35.5,76.5)    |
| AGE                | Weight (kg)        | CmaxSSRatios     | AUC24SSRatios    | %T>MICoflmg/LRatios | %T>MICoflmg/LRatios | %T>MICof2mg/LRatios |
|                    | 52.8 (36.9,75.1)   | 1.00             | 1.13             | 1.18                | 1.18                | 1.18                |
|                    | 28.5 (19.3,46.6)   | 1.14             | 1.18             | 1.09                | 1.09                | 1.15                |

Ratios based on summary of 100 trials. Ratios are relative to adult dosing regimen and represent ratio of paediatric median to adult median for adult dose of 600 mg q12h 1 hr inf.

A 12 mg/kg q12h regimen in this subgroup (maintaining the maximum 400 mg) gave results that were very comparable to 9 mg/kg q12h so that estimates were again very similar to those in adults.

Table 26 Median(90%PI),  ceftaroline  Cmax,  ss,  AUC24,  ss,  %T&gt;MIC  by  age  for  moderate renal  impairment  following  12  mg/kg  (max  of  400  mg)  q12h  dosing  (1  hour infusion) to steady-state for ceftaroline in paediatric patients based on simulations

<!-- image -->

| AGE                 | Weight (kg)      | CmaxSS (mg/L)    | AUC24SS (mg'hr/L)   | %T>MICoflmg/L    | %T>MICof2mg/L    |
|---------------------|------------------|------------------|---------------------|------------------|------------------|
| Adults 600mgq12h1hr | 77.6(52.5,105)   | 20.9 (11.9,36.8) | 97.7(58.9,165)      | 64.5 (44.6,93.4) | 45.5 (29.8,68.7) |
| 12-<18years         | 52.8 (36.9,75.1) | 21.3(11.9,37.2)  | 113(68.1,192)       | 76.9(53.7,100)   | 54.5(35.5,81.9)  |
| 6-<12years          | 28.5(19.3,46.6)  | 30.4(17.8,48.0)  | 147 (91.8,234)      | 76.9 (54.5,100)  | 57.9 (40.5.85.1) |

<div style=\"page-break-after: always\"></div>

Ratios based on summary of 100 trials. Ratios are relative to adult dosing regimen and represent ratio of paediatric median to adult median for adult dose of 600 mg q12h 1 hr inf.

<!-- image -->

The  MAH  acknowledged  that  using  the  updated  POPPK  model,  the  predicted  exposure  estimates  from q12h  have  changed  such  that  Cmax  was  more  aligned  with  the  adult  data.  The  basis  for  the  MAH proposal  of  thrice  daily  dosing  in  adolescents  relied  on  the  fact  that  i)  the  predicted  exposure  in adolescents dosed was seen by the MAH to be more comparable than q12h dosing to the adult exposures using the approved regimen, that ii) thrice daily dosing was predicted to provide improved PTA over q12h dosing and that iii) the safety pool generated in paediatric clinical trials was considered reassuring and supportive than the evidence for the q12h dosing.

On the first  point,  CHMP  analysed  the  comparisons  between  adolescents  and  adults  with  normal  renal function or mild renal impairment using 600 mg q12h (or 18 mg/kg q12h up to 33 kg) and concluded that the claim that the predicted exposure in adolescents dosed q8h is more comparable than q12h dosing to the  adult  exposures  using  the  approved  regimen  was  not  well  justified.  Taking  also  into  account  that safety issues for ceftaroline associated with a &lt;1.5-fold increase in Cmax that would arise if adolescents of  at  least  33  kg  were  to  be  given  600  mg  q12h  were  unlikely,  CHMP  was,  based  on  the  additional simulation data provided by the MAH, of the view that once adolescents (above 12 years of age) reach 33 kg they could be treated with 600 mg q12h.

At the same time it was considered that children aged 2-&lt;18 years of &lt; 33 kg could receive the proposed dose  of  12  mg/kg  q8h.  All  of  the  above  were  agreed  upon  by  the  MAH  and  the  updated  dose recommendation was implemented in the Zinforo PI.

Furthermore, the MAH proposed to also apply the adult dose adjustments for severe renal impairment to adolescents from 12 years and from 33 kg body weight. CHMP considered this proposal to be acceptable. The MAH presented the simulation for children aged from 12 years and with body weight from 33 kg with severe renal impairment if given the recommended adult dose adjustment (reduction to 300 mg q12h). Compared with adults with normal renal function dosed with 600 mg q12h the adjusted dose in this age and  weight  subset  provides  a  similar  Cmax  and  slightly  higher  AUC  and  hence  higher f %T&gt;MIC. The slightly higher predicted AUC falls between that observed in adults with normal renal function given 600 mg q12h and 600 mg q8h.

The  results  are  based  on  simulating  9  mg/kg  q12h  with  a  cap  at  the  adult  dose  for  severe  renal impairment (300 mg q12h), which is reached at 33 kg.

<div style=\"page-break-after: always\"></div>

Table 27 Median (90% PI) ceftaroline Cmax, ss, AUC24,ss, %T&gt;MIC by age for severe renal impairment following 9 mg/kg (max of 300 mg) q12h dosing (1h infusion) to steady-state for ceftaroline in paediatric patients based on simulations

<!-- image -->

medlan(sh,g5uh)basedonsummaryof1ootralsandcorresponds(omedlan(90%predicllon Interval).

The  simulation  for  6  mg/kg  q12h  in  this  subset  also  compared  well  with  adult  exposures  (see  table extract below) but the difference in AUC vs. 9 mg/kg q12h as shown above, which allows for a simple strategy  of  applying  the  adult  dose  adjustments  to  adolescents  of  at  least  33  kg  body  weight,  seems unlikely to be clinically important in terms of safety.

<!-- image -->

The applicant's additional proposal to apply the adult dose adjustments for severe renal impairment and ESRD to adolescents from 12 years and from 33 kg body weight was also considered to be acceptable by CHMP. This has not been simulated but there will be very few such patients and all other simulations do suggest that the adult regimens are suitable for this age and weight subset.

## 2.3.3. Discussion on clinical pharmacokinetics

The MAH's proposal for the Zinforo SmPC in the initial submission was as follows:

| Age/weight range        | Dose    | Frequency     |   Infusion time (minutes) |
|-------------------------|---------|---------------|---------------------------|
| 2 months to < 24 months | 8 mg/kg | every 8 hours |                        60 |
| ≥ 24 months (≤ 33 kg)   | 12mg/kg | every 8 hours |                        60 |
| ≥ 24 months (> 33 kg)   | 400 mg  | every 8 hours |                        60 |

<div style=\"page-break-after: always\"></div>

CHMP  agreed  that  the  MAH's  approach  to  dose  finding  in  paediatric  patients  has  been  broadly appropriate.

CHMP considered that the adjustment of the dose for the age range 6-&lt; 24 months to reduce this to 8 mg/kg  q8h  rather  than  the  12  mg/kg  q8h  that  was  actually  studied  seemed  appropriate,  giving  a standard dose across the age range 2-&lt; 24 months.  During the procedure, the MAH explained the lack of dose  recommendations  for  patients  &lt;  2  months  at  this  time  point,  but  clarified  that  these  will  be proposed for regulatory review in the future. CHMP agreed to this proposal.

It was also agreed by CHMP that adolescents with a body weight of less than 33 kilograms would receive the  same 12 mg/kg dose administered every eight hours, whereas adolescents with a body weight of more or equal than 33 kg would receive the adult dose (600 mg every 12 hours).

The final agreed posology in children with normal renal function is:

| Age/weight range                  | Dose     | Frequency      |   Infusion time (minutes) |
|-----------------------------------|----------|----------------|---------------------------|
| ≥2 months to < 2 years            | 8 mg/kg  | every 8 hours  |                        60 |
| ≥ 2 years to <12 years (< 33 kg)  | 12mg/kg* | every 8 hours  |                        60 |
| ≥ 12 years to <18 years (< 33 kg) | 12mg/kg* | every 8 hours  |                        60 |
| ≥ 12 years to <18 years (≥33 kg)  | 600 mg   | every 12 hours |                        60 |

*the dose administerd every 8 hours should not exceed 400 mg

The adequate posology for children above the age of 2 months depending of their renal function status was also agreed.

The POPPK model was considered very complex by CHMP, but was deemed comprehensive and the fact that the MAH report included extensive diagnostic plots was appreciated. It could be concluded that the model appeared to be appropriate for use in predicting doses for children.

## 2.3.4. Conclusions on clinical pharmacology

No  outstanding  issues  remain.  CHMP  agreed  that  the  PK  evidence  presented  during  this  procedure  is supportive for the agreed changes to the PI.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Main studies

## D3720c00004 (P903-23) acute bacterial skin and skin structure infections

This was a multicentre, randomized, observer-blinded, active-controlled, parallel-group study to evaluate the efficacy, safety, and PK of intravenous (IV) ceftaroline versus IV comparator (vancomycin or cefazolin with or without aztreonam) in children aged 2 months to &lt; 18 years with ABSSSI.

Eligible patients were to have ABSSSI defined as:

- Abscess:  presence  of  a  loculated  fluid  collection  with  erythema,  oedema  or  induration  that extended  from  the  abscess  margin  and  onset  within  7  days  before  randomisation.  A  'major abscess'  either  extended  to  deeper  soft  tissue  or  required  significant  surgical  intervention. Incision and drainage was to be conducted within 24 h after first dose of IV study drug.
- Wound infection: presence of either purulent/seropurulent discharge from the surgical/traumatic wound  with  erythema,  oedema  or  induration  that  surrounded  the  wound  margin.  Onset  of infection must have occurred within 7 days before randomisation and within 30 days following the trauma or surgical procedure.
- Cellulitis/erysipelas:  presence  of  advancing  erythema,  induration/oedema  and  heat  with  onset within 7 days before randomisation.

In  addition  at  least  1  of  the  following  local  signs  and  symptoms  of  acute  infection  were  to  have  been present for &lt; 10 days:

- Purulent or seropurulent drainage or discharge
- Induration/oedema
- Fluctuance
- Heat or localized warmth

AND the presence of at least 1 of the following signs:

- Fever (&gt; 38°C [100.4°F]) or hypothermia (&lt; 35°C [95.0°F]); not axillary
- WBC count &gt; 12,000/mm 3
-  10% immature neutrophils (bands) regardless of total peripheral WBC
- Lymphangitic spread

Block 2:1 randomisation (IXRS) was used to assign patients to ceftaroline (min 180) or comparator (min 90). Stratification was by age cohort and region. Enrolment was in 4 cohorts as follows:

- Cohort 1: children from 12 years to &lt; 18 years
- Cohort 2: children from 6 years to &lt; 12 years
- Cohort 3: children from 24 months to &lt; 6 years
- Cohort 4: young infants/toddlers from 2 months to &lt; 24 months

Efforts  were  made to enrol  at  least  27  (10%) in  each  of  the  age  cohorts.  The  IXRS  was  also  used to assign patients at a 1:1 ratio to PK schedule 1 or 2 for the collection of blood samples for PK analysis.

<div style=\"page-break-after: always\"></div>

Ceftaroline fosamil was dosed using 1-h infusions q8h as follows:

- o ≥ 6 months: 12 mg/kg if ≤ 33 kg or 400 mg if &gt; 33 kg
- o &lt; 6 months: 8 mg/kg

The comparator group received one of the following (dose adjustments were allowed):

- o IV vancomycin 15 mg/kg infused over 60 minutes every 6 hours
- o IV cefazolin 75 mg/kg infused over 60 (± 10) minutes every 8 hours
- o Optional aztreonam 30 mg/kg infused over 60 (± 10) minutes every 8 hours

Treatment was for a maximum of 14 days. A switch to an open-label oral drug on or after Day 4 was allowed if all of the protocol-specified criteria were met (cephalexin [preferred] , clindamycin or linezolid).

A DSMB reviewed safety data from this study.

The overall study design and visits were as shown in the following figure:

Figure   1 D3720c00004 (P903-23) study design

<!-- image -->

The study was descriptive so there was no rationale for the study size.

## Results

Of the 163 enrolled there were 159 treated patients, all of whom had a confirmed diagnosis of ABSSSI and were included in the MITT population while 74 (45%) were included in the mMITT population (had a

<div style=\"page-break-after: always\"></div>

baseline pathogen). The majority (90.2% and 92.6% per treatment group) completed study drug therapy and the study.

Table 28 Subject disposition and reason for premature discontinuations-ITT population

| SubjectStatus ReasonforDiscontinuation/Withdrawal        | Ceftaroline (N = 110) n (%)   | Comparator (N = 53) n (%)   | Total (N =163) n (%)   |
|----------------------------------------------------------|-------------------------------|-----------------------------|------------------------|
| Completedstudydrug                                       | 100 (90.9)                    | 47 (88.7)                   | 147 (90.2)             |
| PrematurediscontinuationofIVstudydrug                    | 7 (6.4)                       | 4 (7.5)                     | 11 (6.7)               |
| Subjectrandomized, but did not receive drug              | 3 (2.7)                       | 1 (1.9)                     | 4 (2.5)                |
| Adverse event                                            | 2 (1.8)                       | 1 (1.9)                     | 3 (1.8)                |
| Withdrewconsent                                          | 2 (1.8)                       | 0                           | 2 (1.2)                |
| Otherreasons                                             | 0                             | 2 (3.8)                     | 2 (1.2)                |
| Prematurediscontinuationoforalstudydrug                  | 3 (2.7)                       | 2 (3.8)                     | 5 (3.1)                |
| Adverse event                                            | 0                             | 1 (1.9)                     | (9:0) 1                |
| RequestofSponsororInvestigator                           | 2 (1.8)                       | 0                           | 2 (1.2)                |
| Withdrew consent                                         | 1 (0.9)                       | 0                           | 1 (0.6)                |
| Lost to follow-up                                        | 0                             | 1 (1.9)                     | 1 (0.6)                |
| Premature discontinuation of any (IV or oral) study drug | 10 (9.1)                      | 6 (11.3)                    | 16 (9.8)               |
| Subjectrandomized,but did not receivedrug                | 3 (2.7)                       | 1 (1.9)                     | 4 (2.5)                |
| Adverse event                                            | 2 (1.8)                       | 2 (3.8)                     | 4 (2.5)                |
| Request ofSponsor orInvestigator                         | 2 (1.8)                       | 0                           | 2 (1.2)                |
| Withdrew consent                                         | 3 (2.7)                       | 0                           | 3 (1.8)                |
| Lost to follow-up                                        | 0                             | 1 (1.9)                     | 1 (0.6)                |
| Otherreasons                                             | 0                             | 2 (3.8)                     | 2 (1.2)                |
| Completedstudy                                           | 103 (93.6)                    | 48 (90.6)                   | 151 (92.6)             |
| Prematurewithdrawalfromstudy                             | 7 (6.4)                       | 5 (9.4)                     | 12 (7.4)               |
| Subject did not meet inclusion/exclusion criteria        | 0                             | 1 (1.9)                     | 1 (0.6)                |
| Withdrew consent                                         | 5 (4.5)                       | 2 (3.8)                     | 7 (4.3)                |
| Lost to follow-up                                        | 0                             | 2 (3.8)                     | 2 (1.2)                |
| Otherreasons                                             | 2 (1.8)                       | 0                           | 2 (1.2)                |

The highest enrolment by age cohort was in Cohort 2 (6 to &lt; 12 years).

| Characteristic                    | Ceftaroline (N=107)   | Comparator (N = 52)   | Total (N = 159)   |
|-----------------------------------|-----------------------|-----------------------|-------------------|
| Age,years                         |                       |                       |                   |
| Mean (SD)                         | 6.99 (5.10)           | 6.94 (5.25)           | 6.97 (5.13)       |
| Median (range)                    | 7.00 (0.2,17.0)       | 6.00 (0.6, 17.0)      | 7.00 (0.2,17.0)   |
| AgeCohort,n(%)                    |                       |                       |                   |
| 12 years to < 18 years (Cohort 1) | 23 (21.5)             | 13 (25.0)             | 36 (22.6)         |
| 6 years to <12 years (Cohort 2)   | 36 (33.6)             | 15 (28.8)             | 51 (32.1)         |
| 24 months to<6 years (Cohort 3)   | 23 (21.5)             | 12 (23.1)             | 35 (22.0)         |
| 2monthsto<24months(Cohort 4)      | 25 (23.4)             | 12 (23.1)             | 37 (23.3)         |

The majority of patients had cellulitis or erysipelas (66%) followed by major abscesses (25%) and the most  common  body  sites  affected  were  similar  between  groups.  Signs  and  symptoms  of  ABSSSI  at baseline were also balanced between treatment groups and most were of moderate to severe intensity. Abscesses had been drained for ~20% per group. The primary infection site areas were similar between treatment groups with median (range) infection areas of 108 cm 2  (3.8, 742.5) and 112 cm 2  (19.3, 874.0) in the comparator group.

Overall 45.9% had Gram-positive pathogens and Staphylococcus aureus was the most common (40.2% and 42.3% per group), of which most were MSSA (18 ceftaroline and 6 comparator patients had MRSA). S . pyogenes was identified for 12.1% in the ceftaroline group and 1.9% in the comparator group. Most (87.8%)  infections  were  monomicrobial.  The  highest  ceftaroline  MICs  observed  were  1  μg/mL  for S. aureus (including MRSA) and 0.015 μg/mL for S. pyogenes .

<div style=\"page-break-after: always\"></div>

Approximately 67% had received prior antibacterial therapy and 57% had been treated for at least 24 hours. Twelve of the 16 (10.1%) who had received &gt; 24 hours of prior therapy were confirmed treatment failures.

At  Study  Day  3  in  the  MITT  Population  the  response  to  treatment  was  similar  between  treatments according to the three parameters shown below.

Table 29 Clinical response at study day 3 by treatment group overall (MITT population)

| Response                                                                                                    | Ceftaroline (N =107) n (%)                                                                                  | Comparator (N = 52) n (%)                                                                                   | Difference                                                                                                  |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Definition1:≥20%reductionfrombaselineinfectionarea                                                          | Definition1:≥20%reductionfrombaselineinfectionarea                                                          | Definition1:≥20%reductionfrombaselineinfectionarea                                                          | Definition1:≥20%reductionfrombaselineinfectionarea                                                          |
| Responder                                                                                                   | 91 (85.0)                                                                                                   | 44 (84.6)                                                                                                   | 0.4%                                                                                                        |
| 95% CI                                                                                                      | (76.9, 91.2)                                                                                                | (71.9, 93.1)                                                                                                | (-10.7, 13.9)                                                                                               |
| Non-responder                                                                                               | 11 (10.3)                                                                                                   | 4 (7.7)                                                                                                     | 一                                                                                                           |
| Incomplete data                                                                                             | 5 (4.7)                                                                                                     | 4 (7.7)                                                                                                     | 一                                                                                                           |
| Definition2:Cessationofspreadmeasuredbytotalinfectionarea                                                   | Definition2:Cessationofspreadmeasuredbytotalinfectionarea                                                   | Definition2:Cessationofspreadmeasuredbytotalinfectionarea                                                   | Definition2:Cessationofspreadmeasuredbytotalinfectionarea                                                   |
| Responder                                                                                                   | 98 (91.6)                                                                                                   | 47 (90.4)                                                                                                   | 1.2%                                                                                                        |
| 95% CI                                                                                                      | (84.6, 96.1)                                                                                                | (79.0, 96.8)                                                                                                | (-7.7, 13.0)                                                                                                |
| Non-responder                                                                                               | 4 (3.7)                                                                                                     | 1 (1.9)                                                                                                     | 一                                                                                                           |
| Incomplete data                                                                                             | 5 (4.7)                                                                                                     | 4 (7.7)                                                                                                     |                                                                                                             |
| Definition 3: Cessation of spread measured by infection length and width separately, and temperature<37.6°C | Definition 3: Cessation of spread measured by infection length and width separately, and temperature<37.6°C | Definition 3: Cessation of spread measured by infection length and width separately, and temperature<37.6°C | Definition 3: Cessation of spread measured by infection length and width separately, and temperature<37.6°C |
| Responder                                                                                                   | 86 (80.4)                                                                                                   | 39 (75.0)                                                                                                   | 5.4%                                                                                                        |
| 95% CI                                                                                                      | (71.6, 87.4)                                                                                                | (61.1, 86.0)                                                                                                | (-7.8, 20.3)                                                                                                |
| Non-responder                                                                                               | 16 (15.0)                                                                                                   | 9 (17.3)                                                                                                    |                                                                                                             |
| Incompletedata                                                                                              | 5 (4.7)                                                                                                     | 4 (7.7)                                                                                                     |                                                                                                             |

Clinical cure rates at TOC in the MITT population were 94.4% for the ceftaroline group and 86.5% for the comparator group, with a treatment difference of 7.9 (95% CI -1.2, 20.2). Clinical cure rates at TOC for the  CE  Population  were  100.0%  for  the  ceftaroline  group  and  97.8%  for the  comparator  group  with a treatment difference of 2.2% (95% CI -1.7, 11.6).

Table   30 Clinical outcomes at TOC by treatment group overall (MITT population)

| Outcome                | Ceftaroline (N=107) n (%)   | Comparator (N =52) n (%)   | Difference   |
|------------------------|-----------------------------|----------------------------|--------------|
| Clinical cure          | 101 (94.4)                  | 45 (86.5)                  | 7.9%         |
| 95% CI                 | (88.2,97.9)                 | (74.2,94.4)                | (-1.2,20.2)  |
| Clinicalfailure        | 0                           | 1 (1.9)                    |              |
| Observedfailure atEOIV | 0                           | 1 (1.9)                    |              |
| ObservedfailureatEOT   | 0                           | 0                          |              |
| Observedfailure atTOC  | 0                           | 0                          |              |
| Indeterminate          | 6 (5.6)                     | 6 (11.5)                   |              |

The  most  common reasons for  an  indeterminate  outcome  were extenuating  circumstances  and  lost  to follow-up. Cure rates by age cohort are shown in the following table.

Table   31 Clinical outcome at the test of cure visit by cohort (MITT population)

<div style=\"page-break-after: always\"></div>

|                       | Cohort1                 | Cohort1                 | Cohort1                            |             |                        | Cohort3                 | Cohort3                 | Cohort3                | Cohort3                | Cohort4                 | Cohort4                 | Cohort4                |
|-----------------------|-------------------------|-------------------------|------------------------------------|-------------|------------------------|-------------------------|-------------------------|------------------------|------------------------|-------------------------|-------------------------|------------------------|
|                       | Ceftaroline （N=23) n(%） | Ceftaroline （N=23) n(%） | Comparator (N=13) （N=36) n(%) n（%） | Ceftaroline | Comparator （N=15) n(%) | Ceftaroline （N=23) n(%） | Ceftaroline （N=23) n(%） | Comparator (N=12) n(%) | Comparator (N=12) n(%) | Ceftaroline (N=25) n(%） | Ceftaroline (N=25) n(%） | Comparator （N=12) n（%） |
| Clinical cure         | 22                      | (95.7)                  | 10 (76.9)                          | 35 (97.2)   | 14 (93.3)              | 22                      | (95.7)                  | 11                     | (91.7)                 | 22                      | (88.0)                  | 10 (83.3)              |
| Clinicalfailure       | 0                       |                         | 0                                  | 0           | 1 (6.7)                | 0                       |                         | 0                      |                        | 0                       |                         | 0                      |
| ObservedfailureatEoIv | 0                       |                         | 0                                  | 0           | 1 (6.7)                | 0                       |                         | 0                      |                        | 0                       |                         | 0                      |
| Observedfailure atEOT | 0                       |                         | 0                                  | 0           | 0                      | 0                       |                         | 0                      |                        | 0                       |                         | 0                      |
| Observedfailure atToC | 0                       |                         | 0                                  | 0           | 0                      | 0                       |                         | 0                      |                        | 0                       |                         | 0                      |
| Indeterminate         | 1                       | (4.3)                   | 3 (23.1)                           | 1 (2.8)     | 0                      | 1                       | (4.3)                   |                        | 1 (8.3)                | 3                       | (12.0)                  | 2 (16.7)               |

In the mMITT population the cure rates at TOC were 94.2% for ceftaroline and 81.8% for comparator. The  clinical  cure  rates  for  the  two  major  pathogens  are  shown  in  the  following  table.  Microbiological responses followed the clinical responses.

Table 32 Clinical outcome at the test of cure visit by baseline pathogen (mMITT population)

|                         |                                              | Ceftaroline (N=52)    |                      |             |                       | Comparator (N=22)     |            |
|-------------------------|----------------------------------------------|-----------------------|----------------------|-------------|-----------------------|-----------------------|------------|
| Baseline Pathogen       | ClinicalOutcome                              | Tissue or Blood n (%) | Tissue n (%)         | Blood n (%) | Tissue or Blood n(%)  | Tissue n (%)          | Blood n(%) |
| Gram-positive organisms |                                              |                       |                      |             |                       |                       |            |
| Staphylococcusaureus    | N1                                           | 43                    | 42                   | 1           | 22                    | 22                    | 0          |
|                         | Clinical cure Clinical failure               | 40 (93.0)             | 39 (92.9)            | (100.0)     | 18 (81.8)             | 18 (81.8) 0           |            |
| MRSA                    | Indeterminate N1                             | 3 (7.0) 18            | 0 3 (7.1) 18         | 0 0         | 4 (18.2) 7            | 4 (18.2)              | 0          |
|                         | Clinical cure Clinical failure Indeterminate | 16 (88.9)             | 16 (88.9) 0 2 (11.1) |             | 4 (57.1) 0            | 7 4 (57.1) 0          |            |
| MSSA                    | N1                                           | 0 2 (11.1)            | 24 23 (95.8)         | 1           | 3 (42.9) 15 14 (93.3) | 3 (42.9) 15 14 (93.3) | 0          |
|                         | Clinical cure Clinical failure               | 25 24 (96.0) 0        |                      | 1(100.0)    | 1                     | 1 (6.7)               |            |
| Streptococcus pyogenes  | N1                                           | 13                    | 13                   | 0           |                       | 1                     |            |
|                         | Indeterminate                                | 1 (4.0)               | 0 1 (4.2)            | 0           | (6.7)                 |                       |            |
|                         | Clinical cure                                |                       | 13（100.0）            |             | （100.0)               | 1(100.0)              |            |
|                         | Clinical failure Indeterminate               | 0 0 0                 |                      |             | 0 0                   | 0 0                   |            |
|                         |                                              | 13(100.0)             | 0                    |             |                       |                       |            |

The same percentages had a favourable microbiological response (i.e. eradication presumed). Colonisation occurred in 2 (3.8%) ceftaroline and 3 (13.6%) comparator patients. No new infections or superinfections occurred during the study. There were no documented relapses and the sustained cure rates at LFU were 99/101 and 45/45.

Outcomes by gender, region, baseline CrCL and type of baseline infection showed comparable or slightly higher cure rates for ceftaroline vs. comparator.

## D3720c00007 (P903-31) community-acquired bacterial pneumonia requiring hospitalization

This was a Phase 2/3 multicentre, randomized, observer-blinded, active-controlled study to evaluate the safety, tolerability, PK, and efficacy of ceftaroline versus ceftriaxone in paediatric patients aged 2 months to &lt; 18 years with CABP requiring hospitalization.

<div style=\"page-break-after: always\"></div>

Eligible patients were to have CABP that required hospitalization and IV antibacterial therapy and which met each of the following criteria:

- I. Fever (temperature &gt; 38.0°C) or hypothermia (temperature &lt; 35.0°C) (not axillary)
- II. New infiltrate(s) compatible with bacterial pneumonia, including a new alveolar/lobar infiltrate or consolidation (based on imaging results or diagnostic testing)
- III. Acute onset or worsening within the previous 5 days before randomisation of at least 2 of the following clinical signs or symptoms:
- Cough
- Tachypnoea, defined as:

2 months to &lt; 12 months: ≥ 50 breaths/min

12 months to &lt; 5 years: ≥ 40 breaths/min

≥ 5 years: ≥ 20 breaths/min

- Dyspnoea
- Grunting
- Sputum production
- Chest pain
- Cyanosis
- Evidence of pneumonia with parenchymal consolidation
- Increased work of breathing (e.g. nasal flaring, chest wall retractions)
- IV.   At least 1 of the following:
- Typical respiratory pathogen identified or isolated from a respiratory   or blood culture
- Leukocytosis (&gt; 15,000 white blood cells [WBC]/mm3)
- &gt; 15% immature neutrophils (bands) regardless of total peripheral WBC
- Leukopenia (&lt; 4500 WBC/mm3) likely due to the bacterial infection
- Hypoxaemia (oxygen saturation &lt; 92% on room air)

Block randomization (3:1) using an IXRS was used to assign patients to ceftaroline (120) or ceftriaxone (40) with stratification by age cohort and region and using the same PK schema as above. Patients were enrolled in 4 cohorts of descending age as described above with a plan to enrol at least 16 (10%) per cohort.

Ceftaroline was dosed as described above. Ceftriaxone was dosed at 75 mg/kg/day up to a maximum of 4 g/day.  Dosing  was  q12h  using  equally  divided  doses  infused  over  30.  A  switched  to  oral  amoxicillin clavulanate up to 90 mg/kg/day in two divided doses (q12h) was allowed on or after Day 4 if protocolspecified criteria were met. The total duration of treatment was to be 5 to 14 days including at least 3 days (7 infusions for ceftaroline) of IV study drug. A DSMB reviewed safety data from this study. The overall study design and visits were as shown in the following figure:

<div style=\"page-break-after: always\"></div>

Figure 2 Study diagram for study D3720c00007 (P903-31)

<!-- image -->

The study was descriptive so there was no rationale for the study size.

## Results

Of the 160 patients treated ~10% had a sole atypical pathogen (note this based only on a baseline IgM assay)  and  were  excluded  from  the  MITT  Population  (88.8%).  The  mMITT  Population  comprised  only 20.5% (33) with an identified typical baseline pathogen. Most (90.7%) patients completed study drug and 95.7% completed the study.

Table 33 Subject completion and reasons for premature discontinuations/withdrawals (ITT population)

| SubjectStatus ReasonforDiscontimuation/Wihdrawal   | Cefaroline (I =N)  (%)   | Cefiriaxone (N=39)  (%)   | Total (N =161)  (%)   |
|----------------------------------------------------|--------------------------|---------------------------|-----------------------|
| Completed study drug                               | 111 (91.0)               | 35 (89.7)                 | 146 (90.7)            |
| Prematurediscontinuationof anyIVstudydrug          | 9 (7.4)                  | 4 (10.3)                  | 13 (8.1)              |
| Subjectrandomized,butdidnotreceivedrug             | 1 (0.8)                  | 0                         | 1 (0.6)               |
| Adverse event                                      | 1 (0.8)                  | 0                         | 1 (0.6)               |
| Pregnancy/nursing during the study                 | 0                        | 0                         | 0                     |
| Request of SponsororInvestigator                   | 0                        | 0                         | 0                     |
| Insufficient therapeuticeffect                     | 5 (4.1)                  | 3 (7.7)                   | 8 (5.0)               |
| Withdrew consent                                   | 1 (0.8)                  | 0                         | 1 (0.6)               |
| Lost to follow-up                                  | 0                        | 0                         | 0                     |
| Other reasons                                      | 1 (0.8)                  | 1 (2.6)                   | 2 (1.2)               |
| Prematurediscontinuationofany(IVororal)study drug  | 11 (9.0)                 | 4 (10.3)                  | 15 (9.3)              |
| Subject randomized, but did not receive drug*      | 1 (0.8)                  | 0                         | 1 (0.6)               |
| Adverse event                                      | 2 (1.6)                  | 0                         | 2 (1.2)               |
| Pregnancy/nursingduringthestudy                    | 0                        | 0                         | 0                     |
| RequestofSponsororInvestigator                     | 0                        | 0                         | 0                     |
| Insufficient therapeutic effect                    | 5 (4.1)                  | 3 (7.7)                   | 8 (5.0)               |
| Withdrew consent                                   | 1 (0.8)                  | 0                         | 1 (0.6)               |
| Lost to follow-up                                  | 0                        | 0                         | 0                     |
| Otherreasons                                       | 2 (1.6)                  | 1 (2.6)                   | 3 (1.9)               |
| Prematurediscontinuationoforalstudydrug            | 2 (1.6)                  | 0                         | 2 (1.2)               |
| Adverse event                                      | 1 (0.8)                  | 0                         | 1 (0.6)               |
| Pregnancy/nursingduringthestudy                    | 0                        | 0                         | 0                     |
| Requestof SponsororInvestigator                    | 0                        | 0                         | 0                     |
| Insufficient therapeuticeffect                     | 0                        | 0                         | 0                     |
| Withdrew consent                                   | 0                        | 0                         | 0                     |
| Lost to follow-up                                  | 0                        | 0                         | 0                     |
| Other reasons                                      | 1 (0.8)                  | 0                         | 1 (0.6)               |

<div style=\"page-break-after: always\"></div>

| Completedstudy                               | 116 (95.1)   | 38(97.4)   | 154 (95.7)   |
|----------------------------------------------|--------------|------------|--------------|
| Prematurewithdrawalfromstudy                 | 6 (4.9)      | 1 (2.6)    | 7 (4.3)      |
| Subjectdidnotmeetinclusion/exclusioncriteria | 0            | 0          | 0            |
| Withdrewconsent                              | 2 (1.6)      | 0          | 2 (1.2)      |
| Losttofollow-up                              | 1 (0.8)      | 1 (2.6)    | 2 (1.2)      |
| WithdrawnbyInvestigator                      | 0            | 0          | 0            |
| Lackofcompliance                             | 0            | 0          | 0            |
| Death                                        | 0            | 0          | 0            |
| Otherreasons                                 | 3 (2.5)      | 0          | 3 (1.9)      |

The highest enrolment was in Cohort 3 (24 months to &lt; 6 years) and the lowest was in Cohort 1 (12 to &lt; 18 years). Hence the mean age was 4.19 years with a range 10 weeks through 17 years.

| Characteristic     | Ceftaroline (N=107)   | Cefiriaxone (N=36)   | Total (N=143)   |
|--------------------|-----------------------|----------------------|-----------------|
| Age,years          |                       |                      |                 |
| Mean±SD            | 4.26±3.45             | 3.98±3.47            | 4.19±3.44       |
| Median(range)      | 3.00(0.2,17.0)        | 3.00(0.4,16.0)       | 3.00(0.2,17.0)  |
| AgeCohort,n(%)     |                       |                      |                 |
| 12yearsto<18years  | 7 (6.5)               | 2(5.6)               | 9(6.3)          |
| 6yearsto<12years   | 19 (17.8)             | 7 (19.4)             | 26 (18.2)       |
| 24monthsto<6years  | 58(54.2)              | 21(58.3)             | 79(55.2)        |
| 2monthsto<24months | 23 (21.5)             | 6 (16.7)             | 29 (20.3)       |

Demographics  and  baseline  characteristics  were  balanced  between  treatment  groups.  Nasopharyngeal swabs for viral PCR were collected. The CSR states that the majority had 1 or more positive findings but no details are given. Approximately one half of patients had prior pneumococcal vaccination.

Baseline  pneumonia  and disease  characteristics  were  generally  similar  between  treatment  groups.  The median CRP was elevated at baseline and higher in the ceftriaxone vs. ceftaroline group. All patients had a  baseline  chest  X-ray,  and  the  majority  had  involvement  of  1  lobe.  A  higher  percentage  in  the ceftriaxone group had an effusion. Most pathogens were identified only by pneumococcal urinary antigen and few respiratory specimens were obtained (11 patients). Two were considered to have M. pneumoniae with a typical pathogen. Blood cultures were obtained from 97.2% but only 4.2% were positive (1 MRSA and 2 per group with S. pneumoniae ).

Nearly  half  (44.8%)  in  the  MITT  population  had  received  systemic  antibacterial  treatment  within  96 hours. Most (30.8%) had received ≤ 24 hours and all of the 14% who had received &gt; 24 hours were confirmed treatment failures.

The clinical response rates on Day 4 (improvement in ≥ 2/7 symptoms and no worsening) were similar between treatments (69.2% ceftaroline vs. 66.7% ceftriaxone; difference 2.5% [95%CI -13.9, 20.9]). The  clinical  cure  rates  at  TOC  were  also  similar  between  groups  in  the  MITT  (87.9%  and  88.9%, respectively), CE (91.8 and 88.9%) and mMITT populations (79.2% and 77.8%; all derived from clinical outcomes.). Rates were comparable in the age cohorts with the largest numbers in the MITT population.

## Table 34

## Clinical outcome at the TOC visit (MITT population)

| Ontcome         | Cefaroline (N=107) 1 (%)   | Cefriaxone (N=36) 1 (%)   | Difference (%)   |
|-----------------|----------------------------|---------------------------|------------------|
| Clinical cure   | 94 (87.9)                  | 32 (88.9)                 | 0'1-             |
| 95%CI           | (80.1,93.4)                | (73.9,96.9)               | (-11.5, 14.1)    |
| Clinicalfailure | 8 (7.5)                    | 4 (11.1)                  |                  |
| AtEOIV          | 7 (7.5)                    | 3 (8.3)                   |                  |
| AtEOT           | 0                          | 1 (2.8)                   |                  |
| AtTOC           | 1 (0.9)                    | 0                         |                  |
| Indeterminate   | 5 (4.7)                    | 0                         |                  |

<div style=\"page-break-after: always\"></div>

|                       | Cohort1                | Cohort1                | Cohort2                  | Cohort2                | Cohort3                 | Cohort3                 | Cohort4                  | Cohort4                |
|-----------------------|------------------------|------------------------|--------------------------|------------------------|-------------------------|-------------------------|--------------------------|------------------------|
|                       | Ceftaroline (N=7) n(%) | Ceftriaxone (N=2) n(S) | Ceftaroline (N=19) n (%) | Ceftriaxone (N=7) n(%) | Ceftaroline (N=58) n(%） | Ceftriaxone (N=21) n(%） | Ceftaroline (N=23) n (%) | Ceftriaxone (N=6) n(8) |
| Clinical cure         | 6(85.7)                | 2（100.0)               | 15(78.9）                 | 6(85.7)                | 50(86.2)                | 18（85.7)                | 23(100.0)                | 6(100.0)               |
| Clinicalfailure       | 1（14.3）                | 0                      | 2（10.5）                  | 1（14.3)                | 5（ 8.6)                 | 3（14.3)                 | 0                        | 0                      |
| ObservedfailureatEoIv | 1（14.3）                | 0                      | 2（10.5）                  | 1（14.3)                | 4（ 6.9)                 | 2（9.5）                  | 0                        | 0                      |
| Observedfailure atEoT | 0                      | 0                      | 0                        | 0                      | 0                       | 1（ 4.8)                 | 0                        |                        |
| Observedfailure atToC | 0                      | 0                      | 0                        | 0                      | 1 1.7)                  | 0                       | 0                        | 0                      |
| Indeterminate         | 0                      | 0                      | 2(10.5)                  | 0                      | 3( 5.2)                 | 0                       | 0                        | 0                      |

No subject had a clinical relapse at the LFU visit. One patient in the ceftaroline group with S. pneumoniae had a new infection ( Haemophilus parainfluenzae ) at TOC visit (Day 25) and was assessed as a clinical failure since this required further antimicrobial therapy.

## D3720c00013 (P903-24) complicated community-acquired bacterial pneumonia

This  was  a  multicentre,  randomised,  observer-blinded,  active-controlled  study  to  evaluate  the  safety, tolerability,  PK,  and  efficacy  of  IV  ceftaroline  fosamil  versus  IV  ceftriaxone  plus  IV  vancomycin  in paediatric patients aged 2 months to &lt; 18 years with complicated CABP. It was designed to enrich for patients at risk for infection due to MRSA.

Eligible  patients  were  to  have  CABP  that  met  criteria  I-IV  as  in  study  P903-31  above  PLUS  confirmed presence of at least one indicator of complicated CABP or staphylococcal pneumonia as follows:

- Empyema defined as the presence of pus and fluid from infected tissue collected in the pleural space as confirmed via thoracentesis
- Pulmonary abscess defined as a collection of pus in the lung
- Necrotizing pneumonia defined as a consolidative pneumonia that has areas of non-enhancement on  contrast-enhanced  CT  but  no  air-fluid  level  or  rim  enhancement  or  development  of  a pneumatocele after the pneumonia
- Pneumatocele defined as a thin-walled, air-containing cyst of the lungs
- Pleural effusion needing chest tube drainage, but not considered an empyema
- Gram-positive cocci in clusters on Gram stain from a respiratory specimen (sputum, pleural fluid, bronchoalveolar lavage, deep tracheal)
- Requirement for positive pressure assisted ventilation
- Previous influenza-like illness (defined as temperature &gt; 38.0°C plus cough or sore throat in the absence  of  a  known  cause  other  than  influenza)  or  documented  influenza  infection  (e.g.  by culture or molecular testing) within 28 days of enrolment
- Severe CABP, defined as requirement for treatment in an intensive care unit

Block randomization, using an IXRS, stratified by age cohort, was used to assign patients (3:1) to the ceftaroline or comparator group (IV ceftriaxone plus IV vancomycin). Patients were to be enrolled in 4 cohorts of descending age as described above.

Ceftaroline fosamil was dosed using 2-h infusions q8h as follows:

≥ 6 months: 15 mg/kg if ≤ 40 kg or 600 mg if &gt; 40 kg

&lt; 6 months: 10 mg/kg

<div style=\"page-break-after: always\"></div>

Ceftriaxone was dosed at 75 mg/kg/day up to a maximum of 4 g/day. Dosing was q12h using equally divided  doses  infused  over  30  min.  Vancomycin  was  dosed  at  15  mg/kg  q6h  infused  over  at  least  60 minutes or at a maximum of 10 mg/min and could be discontinued after 72 hours of IV study drug if MRSA,  PRSP  or  PISP  was  not  confirmed  or  suspected.  At  study  centres  where  trough  levels  were measured as standard of care the values were recorded in the eCRF.

A  switch  to  open-label  oral  study  drug  (amoxicillin  clavulanate,  clindamycin,  or  linezolid;  selected according to known or documented organisms and susceptibility) could occur after 72 hours of IV study drug if the criteria for oral switch were met.

- o Amoxicillin clavulanate was dosed at 45 to 90 mg/kg/day divided q12h
- o Clindamycin was dosed at 13 mg/kg q8h
- o Linezolid was dosed at 600 mg q12h (Cohort 1) or 10 mg/kg q8h (Cohorts 2, 3 and 4)

The total duration of study drug therapy was 5 to 21 days. A DSMB reviewed safety data from this study.

The overall study design and visits were as shown in the following figure:

Figure   3 D3720c00013 (P903-24) study design

<!-- image -->

The study was descriptive so there was no rationale for the study size.

## Results

Of  40  patients  enrolled  (30  ceftaroline)  two  (one  per  treatment  group)  were  excluded  from  the  MITT population  due  to  having  a  sole  atypical  pathogen.  There  were  18  (45%)  with  at  least  one  typical pathogen (mMITT population). The mean age was 5.4 years (range 16 weeks through 17 years). None had CrCL &lt; 50 ml/min but one had CrCL of 355.2 mL/min/1.73m² with serum creatinine of 8.8 μmol/L. Seven  had  a  history  of  pneumococcal  vaccination.  Baseline  pneumonia  disease  characteristics  were similar  between  treatment  groups.  Approximately  40%  had  pleural  effusion  and  60%  had  multi-lobar involvement.

<div style=\"page-break-after: always\"></div>

Table 35

## Demographic and baseline characteristics (MITT population)

| Characteristic     | Ceftaroline (N =29)   | Comparator (N=9)   | Total (N=38)    |
|--------------------|-----------------------|--------------------|-----------------|
| Age, years         |                       |                    |                 |
| Mean (SD)          | 5.31 (4.65)           | 5.74 (5.18)        | 5.4 (4.71)      |
| Median(range)      | 4.00 (0.3,17.0)       | 4.00 (0.3, 16.0)   | 4.00 (0.3,17.0) |
| Age Cohort,n (%)   |                       |                    |                 |
| 12yearsto<18years  | 4 (13.8)              | 2 (22.2)           | 6 (15.8)        |
| 6yearsto<12years   | 7 (24.1)              | 1 (11.1)           | 8 (21.1)        |
| 24monthsto<6years  | 12 (41.4)             | 4 (44.4)           | 16 (42.1)       |
| 2monthsto<24months | 6 (20.7)              | 2 (22.2)           | 8 (21.1)        |

Nasopharyngeal swabs were collected from the majority and most had one or more findings positive for viral testing by PCR but details are not provided. Respiratory samples were obtained from 17 patients (11 ceftaroline). Staphylococcus aureus was cultured from 4 ceftaroline and 1 comparator patients. Two in the ceftaroline group had positive blood cultures. A third had a urinary antigen test that was positive for S. pneumoniae .

More  than  half  (62.1%  ceftaroline  and  55.6%  comparator)  had  received  prior  systemic  antibacterial medications within 96 hours. All patients who had &gt; 24 hours prior (20.7% in the ceftaroline group and 11.1% in the comparator group) were confirmed treatment failures.

On Day 4 the clinical response (defined as above) rates were 51.7% in the ceftaroline group and 66.7% in the comparator group.

Clinical cure rates at TOC were 89.7% ceftaroline vs. 100% comparator in the MITT population, 88.5% vs. 100%, respectively, in the CE population and 86.7% vs. 100%, respectively, in the mMITT population. Three MITT patients in the ceftaroline group were clinical failures  but  only one  was  due  to insufficient therapeutic effect (the other two discontinued due to AEs). All but 2 in the ceftaroline group and all in the comparator group had a favourable microbiological outcome at TOC in the mMITT Population.

## 2.4.2. Discussion on clinical efficacy

CHMP agreed that overall the efficacy findings are very supportive of the likely adequacy of the regimens tested in the various age groups, despite several limitations (e.g. the allowance for oral switch to other agents). As discussed in the clinical pharmacology section, the final dose recommendations in the SmPC are  not  identical  to  those  studied  clinically.  Nevertheless,  CHMP  agreed  that  the  amended  doses  are predicted to be adequate.

## 2.4.3. Conclusions on the clinical efficacy

No  outstanding  issues  could  be  identified.  CHMP  agreed  that  the  available  efficacy  data  are  broadly supportive.

## 2.5. Clinical safety

## Safety in special populations

## D3720c00004 (P903-23) acute bacterial skin and skin structure infections

The median duration of IV treatment was 5.0 days in each treatment group and most received 3 - 8 days. No comparator group patients received aztreonam. The median duration of total (IV + PO) therapy was

<div style=\"page-break-after: always\"></div>

10 days. A switch to oral occurred in 59% after a median time of 4 days and with a median duration of 8.0 days in each treatment group. The most commonly used oral treatment was cephalexin.

The following table summarises the AE rates:

Table 36 Summary of Adverse Events by treatment group overall (safety population)

| AdverseEventCategory                                     | Ceftaroline (N=106) n (%)   | Comparator (N=53) n (%)   | Total (N = 159) n (%)   |
|----------------------------------------------------------|-----------------------------|---------------------------|-------------------------|
| Numberofsubjectswith:                                    |                             |                           |                         |
| Any TEAE                                                 | 51 (48.1)                   | 23 (43.4)                 | 74 (46.5)               |
| Any study drug-related TEAEs                             | 23 (21.7)                   | 12 (22.6)                 | 35 (22.0)               |
| AnySAEs                                                  | 4 (3.8)                     | 1 (1.9)                   | 5 (3.1)                 |
| Any study drug-related SAEs                              | 2 (1.9)                     | 0                         | 2 (1.3)                 |
| Discontinuations of any study drug (IV or oral) due toAE | 4 (3.8)                     | 2 (3.8)                   | 6 (3.8)                 |
| Discontinuationsof anyIVstudydrugduetoAE                 | 2 (1.9)                     | 1 (1.9)                   | 3 (1.9)                 |
| Deaths                                                   | 0                           | 0                         | 0                       |

Treatment-emergent AEs were more common in Cohort 4 (the youngest) than in other Cohorts (70.8% ceftaroline and 61.5% comparator vs. &lt;50% in all other cohorts). The most frequently occurring TEAEs in the  ceftaroline  group  were  diarrhoea,  rash  (8  [7.5%]  each)  and  vomiting  (7  [6.6%]).    Diarrhoea  and vomiting were also the most frequently reported TEAEs in the comparator group.

Table 37 Treatment-emergent adverse events reported by at least 2% of patients by treatment group overall (safety population)

| System Organ Class PreferredTerm\"               | Ceftaroline (N = 106) n(%)   | Comparator (N = 53) n (%)   |
|-------------------------------------------------|------------------------------|-----------------------------|
| Subjectswith≥1TEAE                              | 51(48.1)                     | 23(43.4)                    |
| Bloodandlymphaticsystemdisorders                |                              |                             |
| Eosinophilia                                    | 5 (4.7)                      | 1 (1.9)                     |
| Gastrointestinaldisorders                       |                              |                             |
| Diarrhea                                        | 8 (7.5)                      | 8 (15.1)                    |
| Vomiting                                        | 7 (6.6)                      | 8 (15.1)                    |
| Nausea                                          | 5 (4.7)                      | 0                           |
| Abdominalpain                                   | 3 (2.8)                      | 1 (1.9)                     |
| Generaldisordersandadministrationsiteconditions |                              |                             |
| Pyrexia                                         | 4 (3.8)                      | 0                           |
| Infections and infestations                     |                              |                             |
| Upperrespiratory tract infection                | 5 (4.7)                      | 1 (1.9)                     |
| Injury,poisoning and procedural complications   |                              |                             |
| Arthropod bite                                  | 0                            | 2 (3.8)                     |
| Nervoussystemdisorders                          |                              |                             |
| Headache                                        | 3 (2.8)                      | 1 (1.9)                     |
| Respiratory,thoracic andmediastinal disorders   |                              |                             |
| Cough                                           | 4 (3.8)                      | 2 (3.8)                     |
| Skinandsubcutaneoustissuedisorders              |                              |                             |
| Rash                                            | 8 (7.5)                      | 2 (3.8)                     |
| Pruritus                                        | 1 (0.9)                      | 3 (5.7)                     |

Most  TEAEs  were  of  mild  intensity.  Severe  TEAEs  were  reported  for  three  patients  per  group  (2.8% ceftaroline  vs.  5.7%  comparator).  Treatment-related  TEAEs  were  reported  for  21.7%  vs.  22.6%;  the most common in the ceftaroline group were rash and eosinophilia (5 patients; 4.7% each vs. 1 patient each in the comparator group).

Six SAEs were reported from 5 patients including 4 [3.8%] in the ceftaroline group and 1 [1.9%] in the comparator group. Two SAEs in different patients in the ceftaroline group ( Clostridium difficile colitis and hypersensitivity) were considered drug-related. Also, two in the ceftaroline group were discontinued from treatment due to SAEs (hypersensitivity and osteomyelitis).

<div style=\"page-break-after: always\"></div>

Table 38 List of serious adverse events (safety population)

| TreatmentGroup SubjectID/Cohort   | Sex/Race Age(y)y   | DateofFirst Last Doseof StudyDrug   | IV/Oral Daysof Therapy   | IvestigatorTerm PreferredTerm/                                  | Dayy/StopDate SAEStartDate (Day)   | Relationshipto Severity/ StudyDrug   | ActionTaken                                        | Outcome              |
|-----------------------------------|--------------------|-------------------------------------|--------------------------|-----------------------------------------------------------------|------------------------------------|--------------------------------------|----------------------------------------------------|----------------------|
| Ceftaroline                       |                    |                                     |                          |                                                                 |                                    |                                      |                                                    |                      |
| 001523001/ Cohort4                | 1.2/F/W            | 07Mar13/ 20Mar13                    | 4/11                     | Pneumoniaviral                                                  | 25Mar13(19) 02Apr13(27)            | Moderate/No                          | None                                               | Recovered/ resolved  |
| 006323001/ Cohortl                | 15/F/W             | 12Sep12/ 30Sep12                    | 3/17                     | colitis/Clostridiumdifficile Clostridiumdifficile enterocolitis | 250ct 12（44)/ 20Nov12（70)          | Severe/Yes                           | None                                               | Recovered/ resolved  |
| 021923002/ Cohort1                | 12/F/W             | 24Jul13/ 01Aug13                    | 9/-                      | Hypersensitivity/allergic reaction                              | 01Aug13(9) 04Aug13(12)             | Moderate/Yes                         | Study drug discontinued/ subject continuedin study | Recovered/ resolved  |
| 170123003/ Cohort2                | 11/M/W             | 22Mar13/ 26Mar13                    | 5/-                      | Ostcomyelitis                                                   | 26Mar13(5) Ongoing                 | Severe/No                            | Studydrug discontinued/ subject continued in study | Recovered/ resolving |
| Comparator                        |                    |                                     |                          |                                                                 |                                    |                                      |                                                    |                      |
| 180223007/ Cohort3                | 3/F/W              | 08Mar14/ 13Mar14                    | 6/-                      | Tonsillitis/purulent tonsillitis,hospital treatment             | 28Mar14(21/ 01Apr 14(25)           | Severe/No                            | None                                               | Recovered/ resolved  |
| 180223007/ Cohort3                | 3/F/W              | 08Mar14/ 13Mar14                    | 6/-                      | Lymphadenitis/acute inflammationofmesenteric lymphnodes         | 06Apr14(30)/ 10Apr14(34)           | Moderate/No                          | None                                               | Recovered/ resolved  |

TEAEs leading to discontinuation of study drug therapy were reported for 3.8% per treatment group (4 and  2  patients)  and  2  vs.  1  discontinued  IV  therapy.  These  included  the  two  discontinuations  of ceftaroline  that  resulted  from  SAEs  and  a  comparator  group  patient  who  discontinued  IV  due  to  nonserious hypersensitivity.

The rate of occurrence of PCS haematology and chemistry values was low, with little difference observed between  treatment  groups.  In  light  of  the  reported  AEs  of  eosinophilia,  PCS  values  occurred  in  two ceftaroline and no comparator group patients.

Table 39 Overall potentially clinically significant postbaseline haematology values based on both normal ranges and percent change from baseline (safety population)

| ClinicalLaboratory Parameter(Unit)    | PCSCriterion                           | Ceftaroline (N=106) 1/N1 (%)   | Comparator (N=53) W/N1 (%)   |
|---------------------------------------|----------------------------------------|--------------------------------|------------------------------|
| Eosinophils (%)                       | >4.00×ULNand>400% increasefromBaseline | 2/100 (2.0)                    | 0/46                         |
| Neutrophils absolutecell count(10°/L) | <0.50×LLNand>70% decreasefromBaseline  | 1/93 (1.1)                     | 2/46 (4.3)                   |
| Neutrophils(%)                        | <0.50×LLNand>70% decreasefromBaseline  | 2/99 (2.0)                     | 2/47(4.3)                    |

Direct  Coombs  test  seroconversion  occurred  in  17.2  %  in  the  ceftaroline  group  and  4.2%  in  the comparator group but no patient had any evidence of haemolytic anaemia or haemolysis.

## D3720c00007 (P903-31) community-acquired bacterial pneumonia requiring hospitalization

Median  exposure  to  IV  study  drug  was  5  days  in  the  ceftaroline  group  and  6  days  in  the  ceftriaxone group. There was a switch to oral study drug in 65% of patients after a median of 6 days IV. The median duration of oral treatment was 6 days. The overall safety data are summarised in the following table:

<div style=\"page-break-after: always\"></div>

## Table 40 Summary of subjects with treatment-emergent adverse events (safety population)

| AdverseEventCategory                                          | Ceftaroline (N = 121) 1 (%)   | Cefriaxone (N= 39) n (%)   | Total (N=160) 1 (%)   |
|---------------------------------------------------------------|-------------------------------|----------------------------|-----------------------|
| Number of subjectswith:                                       |                               |                            |                       |
| Any TEAE                                                      | 55 (45.5)                     | 18 (46.2)                  | 73 (45.6)             |
| Any study drug-related TEAEs                                  | 12 (9.9)                      | 3 (7.7)                    | 15 (9.4)              |
| Any SAEs                                                      | 6 (5.0)                       | 1 (2.6)                    | 7 (4.4)               |
| Any(IV or oral) study drug-related SAEs                       | 0                             | 0                          | 0                     |
| Discontinuations due to any (IV or oral) study drug due to AE | 3 (2.5)                       | 0                          | 3 (1.9)               |
| Discontinuations of IV studydrugduetoAE                       | 2 (1.7)                       | 0                          | 2 (1.3)               |
| Deaths                                                        | 0                             | 0                          | 0                     |

The most commonly reported events in each treatment group were gastrointestinal events (diarrhoea and vomiting).

## Table 41 Treatment-emergent adverse events reported by at least 3% of subjects (safety population)

| SystemOrganClass/ PreferredTerm                  | Ceftaroline (N =121)  (%)   | Cefiriaxone (N =39)  (%)   |
|--------------------------------------------------|-----------------------------|----------------------------|
| Blood and lymphaticsystem disorders              |                             |                            |
| Thrombocytosis                                   | 2 (1.7)                     | 3 (7.7)                    |
| Gastrointestinaldisorders                        |                             |                            |
| Diarrhoea                                        | 10 (8.3)                    | 2 (5.1)                    |
| Vomiting                                         | 4 (3.3)                     | 2 (5.1)                    |
| Generaldisordersand administrationsiteconditions |                             |                            |
| Pyrexia                                          | 3 (2.5)                     | 2 (5.1)                    |
| Infectionsandinfestations                        |                             |                            |
| Otitismedia                                      | 1 (0.8)                     | 3 (7.7)                    |

Most  TEAEs  were  assessed  by  the  Investigators  as  mild  or  moderate  in  severity.  Severe  TEAEs  were reported for 3 (2.5%) in the ceftaroline group (thrombocytosis, infectious plural effusion and Kawasaki's disease)  and  for  one  (2.6%)  in  the  ceftriaxone  group  (2  TEAEs:  thrombocytosis  and  pulmonary thrombosis). TEAEs considered to be related to study drug occurred in 9.9% in the ceftaroline group and 7.7% in the ceftriaxone group. The most common in the ceftaroline group were diarrhoea (4), urticaria (2) and elevated transaminases (AST 2 and ALT 1). In the ceftriaxone group the TEAEs considered related were vulvovaginal erythema and dermatitis (1 each) and elevated AST/ALT in one patient.

There were 8 SAEs reported from 7 patients (6 in the ceftaroline group reporting 7 SAEs), most of which were  infections  and  infestations  and  none  was  considered  related  to  study  drug  treatment  or  led  to discontinuation of assigned treatment (see following table).

Three (2.5%) in the ceftaroline group and none in the ceftriaxone group prematurely discontinued study drug  due  to  AEs.  Two  discontinued  from  IV  treatment  because  of  headache  and  one  because  of  the change in diagnosis of Kawasaki's disease. The other discontinued oral therapy.

<div style=\"page-break-after: always\"></div>

Table 42 List of serious adverse events (safety population)

<!-- image -->

| TreatmentGroup SubjectID/Cohort   | Age(y)/ Sex/Race   | DateofFirst/ LastDoseof StudyDrug   | Daysof Therapy IV/Oral   | PreferredTerm/ InvestigatorTerm                      | SAEStartDate Day)/StopDate (Day)   | Severityy Relationshipto StudyDrug   | ActionTaken   |
|-----------------------------------|--------------------|-------------------------------------|--------------------------|------------------------------------------------------|------------------------------------|--------------------------------------|---------------|
| Ceftaroline                       |                    |                                     |                          |                                                      |                                    |                                      |               |
| Cohort3 002331001/                | 2/M/W              | 14Jan13/ 25Jan13                    | 4/9                      | Pncumoniarespiratory syncytialviral/RSV pneumonia    | 25Jan13(12) 08Feb13 (26)           | Moderate/No                          | None          |
| 021931013/ Cohort3                | 3/F/W              | 20Oct13/ 02Nov13                    | 14/-                     | Infectious pleural cffusion /Phyothorax              | 04Nov13（16)/ 22Nov13(34)           | Severe/No                            | None          |
| 140931001/ Cohort3                | 5/M/W              | 16May13/ 22May13                    | 4/4                      | Dehydration/dehydration                              | 23May13(8) 26May13 (11)            | Moderate/No                          | None          |
|                                   |                    |                                     |                          | Gastroenteritis gastroenteritis                      | 23May13(8) 27May13(12)             | Moderate/No                          | None          |
| Cohort3 141331004/                | 4/F/W              | 09Jan14/ 16Jan14                    | 8/-                      | Gastroenteritis/ gastroenteritis                     | 20Jan14（12) 24Jan14 (16)           | Moderate/No                          | None          |
| 141731006/ Cohort4                | 1.2/M/W            | 12Sep13/ 18Sep13                    | 4/4                      | Bronchitis/Obstructive bronchitis                    | 10Oct13(29/ 140ct 13(33)           | Mild/No                              | None          |
| 141731008/ Cohort2                | 6/F/W              | 24Sep13/ 27Sep13                    |                          | Pncumonia/Long-lasting leftsidepneumonia             | 140ct13(21)/ 220ct13(29)           | Mild/No                              | None          |
| Ceftriaxone                       |                    |                                     |                          |                                                      |                                    |                                      |               |
| 202931001/ Cohort3                | 4/M/W              | 10Dec13/ 23Dec13                    | 12/3                     | Pulmonarythrombosis/ Left lower lobe (lung) thrombus | 07Jan14(29) 11 Jan 14(33)          | Severe/No                            | None          |

The  rate  of  occurrence  of  PCS  haematology  values  was  low  with  little  differences  observed  between treatment groups.

Table 43 Potentially clinically significant postbaseline haematology values (safety population)

| ClinicalLaboratoryParameter(Unit)   | PCSCriterion              | Ceftaroline (N=121) W/NI (%)   | Cefiriaxone (N=39) (%)IN/!   |
|-------------------------------------|---------------------------|--------------------------------|------------------------------|
| Neutrophilsabsolutecellcount（10/L)  | <0.5xLLNand>70%decrease   | 1/111(0.9)                     | 0/34                         |
|                                     | >2.20xULNand>100%increase | 111/0                          | 0/34                         |
| Neutrophils(%)                      | <0.5xLLNand>70%decrease   | 1/118(0.8)                     | 1/39 (2.6)                   |
|                                     | >2.20xULNand>100%increase | 0/118                          | 0/39                         |
| Plateletcount（thrombocytes)(10/L)   | <0.4xLLNand>40%decrease   | 611/0                          | 0/39                         |
|                                     | >2.0xULNand>100%increase  | 3/119(2.5)                     | 5/39 (12.8)                  |
| Redbloodcellcount（10'²/L)           | <0.8xLLNand>20%decrease   | 0/119                          | 2/39 (5.1)                   |
| Redbloodcellcount（10'²/L)           | >1.3xULNand>30%increase   | 611/0                          | 0/39                         |

Three patients had elevated liver chemistry values but none met Hy's Law.

Table 44 Potentially clinically significant postbaseline chemistry values (safety population)

| ClinicalLaboratoryParameter(Unit)/PCSCriterion   | Ceftaroline (N= 121) (%) IN/!I   | Cefriaxone (N=39) (%)IN/I   |
|--------------------------------------------------|----------------------------------|-----------------------------|
| AlanineaminotransferaseU/L                       |                                  |                             |
| >3.0xULNand>300%increase                         | 1/115 (0.9)                      | 1/35 (2.9)                  |
| AspartateaminotransferaseU/L                     |                                  |                             |
| >3.0xULNand>300%increase                         | 1/115 (0.9)                      | 1/35 (2.9)                  |
| Potassium(mmol/L)                                |                                  |                             |
| <0.8xLLNand>15%decrease                          | 0/114                            | 2/36 (5.6)                  |
| >1.2xULNand>20%increase                          | 2/114 (1.8)                      | 0/36                        |

A shift from negative at baseline to a positive Coomb's test was found in 17% in the ceftaroline group and 2.7% in the ceftriaxone group. No evidence of haemolytic anaemia or haemolysis was identified in the study.

## D3720c00013 (P903-24) complicated community-acquired bacterial pneumonia

The median duration of treatment with IV study drug was 9 days in the ceftaroline group and 7.5 days in the comparator group. In both treatment groups most switched to oral study drug (73.3% ceftaroline and

<div style=\"page-break-after: always\"></div>

100% comparator) with a median time to switch on Day 8 in both groups. In those who switched the median exposure to oral study drug was 7.5 days in each group. The overall safety profile is summarised in the following table:

Table   45 Summary of adverse events (safety population)

| AdverseEventCategory                                   | Ceftaroline (N= 30)  (%)   | Comparator (N =10)  (%)   | Total (N= 40) 1 (%)   |
|--------------------------------------------------------|----------------------------|---------------------------|-----------------------|
| Numberofsubjectswith:                                  |                            |                           |                       |
| AnyTEAE                                                | 12 (40.0)                  | 8 (80.0)                  | 20 (50.0)             |
| Any(IVororal)studydrug-related TEAEs                   | 7 (23.3)                   | 3 (30.0)                  | 10 (25.0)             |
| Any SAEs                                               | 0                          | 1 (10.0)                  | 1 (2.5)               |
| Any(IVororal)studydrug-relatedSAEs                     | 0                          | 0                         | 0                     |
| Discontinuations of any(IV or oral) study drug duetoAE | 3 (10.0)                   | 0                         | 3 (7.5)               |
| DiscontinuationsofIVstudydrugduetoAE                   | 2 (6.7)                    | 0                         | 2 (5.0)               |
| Deaths                                                 | 0                          | 0                         | 0                     |

TEAEs reported by at least 3 ceftaroline or 2 comparator group patients are shown below.

Table 46 Treatment emergent adverse events reported by at least 3 subjects in the ceftaroline group or 2 subjects in the comparator group (safety population)

| SystemOrganClass PreferredTerm      | Ceftaroline (N=30)  (%)   | Comparator (N=10) 1 (%)   |
|-------------------------------------|---------------------------|---------------------------|
| Subjcctswith≥1TEAE                  | 12 (40.0)                 | 8 (80.0)                  |
| Bloodandlymphaticsystemdisorders    |                           |                           |
| Anemia                              | 3 (10.0)                  | 0                         |
| Gastrointestinaldisorders           |                           |                           |
| Vomiting                            | 2 (6.7)                   | 2 (20.0)                  |
| Infectionsandinfestations           |                           |                           |
| Viralupperrespiratorytractinfection | 0                         | 2 (20.0)                  |
| Skinandsubcutaneoustissuedisorders  |                           |                           |
| Pruritus                            | 3 (10.0)                  | 0                         |

One patient  in  the  ceftaroline  group  had  TEAEs  assessed  as  severe  (AST  increase  and  ALT  increase). Drug-related TEAEs were reported for 23.3% ceftaroline and 30% comparator patients.

Table 47 Incidence of treatment emergent adverse events related to study drug (safety population)

| SystemOrganClass PreferredTerm                  | Ceftaroline (N=30)  (%)   | Comparator (N =10)  (%)   |
|-------------------------------------------------|---------------------------|---------------------------|
| Subjectswith≥1relatedTEAE                       | 7 (23.3)                  | 3 (30.0)                  |
| Bloodandlymphaticsystemdisorders                |                           |                           |
| Eosinophilia                                    | 1 (3.3)                   | 0                         |
| Gastrointestinaldisorders                       |                           |                           |
| Vomiting                                        | 1 (3.3)                   | 0                         |
| Dianhea                                         | 1 (3.3)                   | 0                         |
| Generaldisordersandadministrationsiteconditions |                           |                           |
| Infusionsiteextravasation                       | 1 (3.3)                   | 0                         |
| Investigationsb                                 |                           |                           |
| ALTincreased                                    | 1 (3.3)                   | 1 (10.0)                  |
| ASTincreased                                    | 1 (3.3)                   | 0                         |
| Transaminasesincreased                          | 1 (3.3)                   | 1 (10.0)                  |
| Skinandsubcutaneoustissuedisorders              |                           |                           |
| Pruritus                                        | 1 (3.3)                   | 0                         |
| Dermatitis diaper                               | 1 (3.3)                   | 0                         |
| Rash                                            | 1 (3.3)                   | 0                         |
| Rash erythematous                               | 0                         | 1 (10.0)                  |
| Rash macular                                    | 1 (3.3)                   | 0                         |
| Redmansyndrome                                  | 0                         | 1 (10.0)                  |

<div style=\"page-break-after: always\"></div>

There were two SAEs (lower respiratory tract viral infection and upper respiratory tract viral infection), which were both reported for the same patient in the comparator group.

Two (10.0%) in the ceftaroline group discontinued IV study drug due to AEs of ALT increased and AST increased  (see  above  under  severe  TEAEs)  in  one  and  rash  and  pruritus  of  moderate  intensity  in  the other. These were considered to be drug-related. A third ceftaroline patient discontinued oral therapy.

## Table 48 List of adverse events leading to discontinuation of study drug by individual subject (safety population)

Table12.3.1.3-2. ListofAdverseEventsLeadingtoDiscontinuationofStudyDrugbyIndividualSubject-SafetyPopulation

| Treatment Group SubjectID/ Cohort   | Age(y) Sex/Race   | Dateof First/LastDose ofStudyDrug   | PreferredTerm InvestigatorTerm                                  | AEStart/ StopDate    | DayofAE Start/Stop   | SAE?/Caused Death?/On Therapy?   | Severity/ Relationshipto StudyDrug   | ActionTaken                                         |
|-------------------------------------|-------------------|-------------------------------------|-----------------------------------------------------------------|----------------------|----------------------|----------------------------------|--------------------------------------|-----------------------------------------------------|
| Ceftaroline                         | Ceftaroline       | Ceftaroline                         | Ceftaroline                                                     | Ceftaroline          | Ceftaroline          | Ceftaroline                      | Ceftaroline                          | Ceftaroline                                         |
| 001124001/ Cohort3                  | 4/M/W             | 27Feb2013/ 07Mar2013                | Aspartateaminotransferase increased/elevatedAST                 | 06Mar2013/ 13Mar2013 | 8/15                 | N-Y                              | Severe/Y                             | Study drug discontinucd, subjectcontinuedinstudy    |
| 001124001/ Cohort3                  |                   |                                     | Alanine aminotransferase incrcased/elevatedALT                  | 06Mar2013/ 18Mar2013 | 8/20                 | N-Y                              | Severe/Y                             | Study drug discontinucd, subjectcontinuedinstudy    |
| Cohortl 001124002/                  | 17/M/W            | 25Apr2013/ 13May2013                | Rashmacular/erythematous macularrashonface,trunk andextremities | 02May2013/ 04May2013 | 8/10                 | N/-Y                             | Moderate/Y                           | subject continued in study Study drug discontinued, |
| 002324001/ Cohort3                  | 5/M/W             | 23Jan2013/ 30Jan2013                | Pruritus/itching                                                | 30Jan2013/ 05Feb2013 | 8/14                 | N-Y                              | Moderate/Y                           | Study drug discontinued, subjectcontinued instudy   |
| 002324001/ Cohort3                  |                   |                                     | Rash/rash                                                       | 30Jan2013/ 05Feb2013 | 8/14                 | N-Y                              | Moderate/Y                           | Study drug discontinucd, subject continued in study |

The rates of PCS haematology and chemistry values were low. No patient met the criteria for Hy's Law.

## Table 49 Overall potentially clinically significant postbaseline haematology values based on both normal ranges and percent change from baseline (safety population)

| ClinicalLaboratory Parameter(Unit)   | PCSCriteria              | Ceftaroline (N=30) W/NI (%)   | Comparator (01=N) n/NI (%)   |
|--------------------------------------|--------------------------|-------------------------------|------------------------------|
| Eosinophilspercent(%)                | >4.0xULNand>400%increase | 1/30(3.3)                     | 0/10                         |
| Lymphocytesabsolutecount (10°/L)     | <0.2xLLNand>70%decrease  | 0/29                          | 0/9                          |
| Lymphocytesabsolutecount (10°/L)     | >2.2×ULNand>100%increase | 1/29 (3.4)                    | 0/9                          |
| Lymphocytespercent(%)                | <0.2xLLNand>70%decrease  | 1/30 (3.3)                    | 0/10                         |
| Lymphocytespercent(%)                | >2.2×ULNand>100%increase | 0/30                          | 0/10                         |
| Plateletcount(thrombocytes) (10°/L)  | <0.4×LLNand>40%decrease  | 0/30                          | 0/10                         |
| Plateletcount(thrombocytes) (10°/L)  | >2.0×ULNand>100%increase | 1/30 (3.3)                    | 2/10 (20.0)                  |
| Redbloodcellcount(1o²/L)             | <0.8×LLNand>20%decrease  | 1/30 (3.3)                    | 0/10                         |
| Redbloodcellcount(1o²/L)             | >1.3xULNand>30%increase  | 0/30                          | 0/10                         |
| Whitebloodcell count(10°/L)          | <0.5×LLNand>60%decrease  | 0/30                          | 0/10                         |
| Whitebloodcell count(10°/L)          | 2.0×ULNand>100%increase  | 0/30                          | 1/10(10.0)                   |

<div style=\"page-break-after: always\"></div>

## Table 50 Overall potentially clinically significant postbaseline chemistry values based on both normal ranges and percent change from baseline (safety population)

| ClinicalLaboratory Parameter(Unit)   | PCSCriteria              | Ceftaroline (N=30) (%)IN/\"   | Comparator (N=10) (%)IN/M   |
|--------------------------------------|--------------------------|------------------------------|-----------------------------|
| ALT(SGPT)(U/L)                       | >3.0xULNand>300%increase | 1/30 (3.3)                   | 0/10                        |
| AST(SGOT)(U/L)                       | >3.0xULNand>300%increase | 1/30 (3.3)                   | 0/10                        |
| Bicarbonate                          | <0.7xLLNand>50%decrease  | 0/28                         | 0/10                        |
| Bicarbonate                          | >1.3xULNand>30%increase  | 1/28 (3.6)                   | 0/10                        |
| Potassium                            | <0.8xLLNand>15%decrease  | 0/30                         | 0/10                        |
| Potassium                            | >1.2xULNand>20%increase  | 1/30 (3.3)                   | 0/10                        |

Direct  Coombs  test  seroconversion  occurred  in  26.1%  in  the  ceftaroline  group  and  none  in  the comparator group. No evidence of haemolytic anaemia or haemolysis was identified.

## 2.5.1. Discussion on clinical safety

The additional safety data do not raise any new concerns compared to the existing adult data. The rate of Coombs test positivity was already noted in adults to be considerably higher than for comparators but thus far has not been linked to haemolytic anaemia. A statement on the safety experience in children has been added to section 4.8 of the Zinforo SmPC.

## 2.5.2. Conclusions on clinical safety

CHMP agreed that the additional safety data assessed in this application do not change the known safety profile for Zinforo.

## 2.5.3. PSUR cycle

The PSUR cycle remains unchanged.

## 2.6. Risk management plan

N/A

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8, 5.2, 5.3 and 6.6 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template which were accepted by the CHMP.

In addition, the list of local representatives in the PL has been revised to amend contact details for the representative of Bulgaria.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A full user consultation with target patient groups on the package leaflet was not performed and it has

<div style=\"page-break-after: always\"></div>

been found acceptable for the following reasons: changes made to the package leaflet were not considered significant and were not affecting its readability.

## 3. Benefit-Risk Balance

CHMP agreed that the nonclinical data provided by the MAH to support the extension of use of ceftaroline to children aged from 2 months onwards were adequate.

The MAH has completed a series of studies, in accordance with the agreed PIP and has used the PK data from treated children to derive dose recommendations that are intended to provide plasma exposures comparable with those in adults. Simulations have shown that the final proposed posology by age and weight  is  likely  to  achieve  the  target  exposures.  In  addition,  CHMP  and  the  MAH  agreed  during  the procedure to the posology which will be recommended for children above the age of 2 months, depending on their age, body weight and renal function status.

Ceftaroline was previously shown to be efficacious in the indications granted for adults (complicated skin and soft tissue infections and community-acquired pneumonia) with an acceptable safety profile typical of that of the cephalosporins. The additional safety and efficacy data in children suggest high efficacy at the doses tested with a similar safety profile as that observed in adults.

Overall, CHMP considered that the extension of use of ceftaroline to children from the age of 2 months for the treatment of complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP) is acceptable and agreed that the benefit-risk ratio for Zinforo in this population is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of indication for Zinforo to include a new population, children from the age of 2 months; as a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated with new information on dosing, PK and safety. The Package Leaflet is updated in accordance. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to align the PI with the latest QRD template 10.0.

The requested variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric

<div style=\"page-break-after: always\"></div>

Investigation Plan P/0074/2014 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication for Zinforo to include a new population, children from the age of 2 months; as a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated with new information on dosing, PK and safety. The Package Leaflet is updated in accordance. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to align the PI with the latest QRD template 10.0.

## Summary

Please refer to the scientific discussion for Zinforo EMEA/H/C/002252/II/0022.